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ABSTRACT 
Background: Cardiac care, including cardiac rehabilitation (CR), is most effective if it is high-
quality. The aim of this study was to describe CR quality, using the recently-developed Canadian 
Cardiovascular Society CR quality indicators (QIs). As secondary and tertiary objectives, site 
differences in quality were measured, and the criterion validity of 4 of the QIs in comparison to 
self-report data were established. 
Methods: Secondary analysis was conducted on an observational, prospective, multi-site CR 
program evaluation cohort. A convenience sample of patients from one of 3 CR programs was 
approached at their first CR visit, and consenting participants completed a survey. Clinical data 
were extracted from charts pre and post-program. Of the 30 CR QIs, 21 (70.0%) were assessable: 
10 process, 9 outcome and 2 structure QIs. 
Results: Of 411 consenting patients, 209 (53.0%) completed CR. The greatest quality was 
observed for assessment of blood pressure (98.1%), communication with primary healthcare at 
CR discharge (94.2%), and patient enrollment (93.7%).  The lowest quality was observed for 
wait time from hospital discharge (9.2%), assessments of blood glucose (42.1%), and lipid 
control (53.0%). Of the 7 QIs that had an established benchmark, quality for 2 (28.6%) was 
above the benchmark (particularly assessment of blood pressure). Significant site differences 
were observed in 11 (64.7%) QIs. The magnitude of quality differences between sites was largest 
for assessment of lipid control (72.6%), assessment of blood glucose control (69.0%), and wait 
time in median days from referral to enrollment (30.6 days). Validity was fair for QIs 2a and 3. 
None to slight validity was found for QI-17, and 18 respectively. 
Conclusion: There is wide variability in CR program quality, both overall and between CR sites. 
Quality improvement in particular aspects of CR care is required.  
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1.0 INTRODUCTION 
Cardiovascular disease (CVD) is a leading cause of death in Canada. Effective secondary 
prevention requires multi-factorial behavioural and risk factor management. Cardiovascular 
Rehabilitation (CR) is a comprehensive outpatient chronic disease management program that is 
designed to improve CV health.
1
 CR programs offer medical assessment, structured programs of 
exercise training, patient and family education, and the delivery of comprehensive CV risk factor 
management strategies. Participation in CR is related to 25% lower mortality when compared to 
usual medical care.
2
 Based on the proven benefits of CR, the American Heart Association 
Guideline for secondary prevention and risk reduction therapy
3
 promote referral to CR as the 
standard of care for acute coronary syndrome, following revascularization, among other 
indications.  
The benefits of CR can be further reinforced by providing the highest quality of care to 
patients. However, there remains a large gap between what we know to be effective CR care and 
what is actually delivered.
4,5
 Quantifying the quality of CR involves translating evidence-based 
recommendations into well-defined measurements of care called Quality Indicators (QIs)
6
. The 
Canadian Cardiovascular Society (CCS) embarked on a process to develop QIs 
(http://bridge.ccs.ca/index.php/en/) to enable quality improvement in care nationally
7
. Thirty CR 
QIs specifically were since developed.
6
 To date 14 of them have been assessed, and a wide 
variation between QIs was observed.
8
 This study will assess 21 CR QIs (10 of which have been 
assessed previously and 11 which have not), through secondary analysis of an evaluation 
database of CR programs within the Greater Toronto Area (GTA).  
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2.0 REVIEW OF LITERATURE 
CVD is a class of diseases that involve the heart or blood vessels. Globally, CVD is high 
in prevalence and incidence, and is the leading cause of mortality.
9,10 
One in every 20 Canadians 
reports being diagnosed with a CV disease, but the actual number with undetected heart disease 
is much higher.
11 
The burden of CVD is expected to increase dramatically over the next decade, 
in part due to the aging population and the rising incidence of diabetes mellitus and obesity.
12
 
While CVD mortality has been declining in Canada due to advances in treatment, there 
are many Canadians living with CVDs.
11 
Over time, this CVD burden becomes more complex, 
and has negative impacts for a patient’s quality of life as well as the Canadian healthcare system. 
CVD is the largest health-related economic cost in Canada with major direct (i.e. hospital care, 
drugs, physician care, other institutional care) and indirect (i.e. mortality, and short and long-
term disability) costs.
13
 This cost has increased over recent years and now amounts to CAD$22 
billion per year, with 3 of the top 4 most expensive health conditions in Canada being CVDs.
12  
Thus, there is a critical need for comprehensive and effective chronic disease management to 
address this health system burden.   
2.1 Cardiac Rehabilitation 
CR programs are effective in managing and controlling chronic CVD. The Canadian 
Association of Cardiovascular Prevention and Rehabilitation (CACPR) defines CR as being a 
hospital or community-based program, with the following components: appropriate medical 
assessment; a multidisciplinary team of healthcare professionals, including a physician; a core 
element of exercise; the ability to provide and/or access approved exercise testing procedures; 
client and family education; structured risk factor identification, and behaviour modification.
1   
Other components include: referrals, patient assessment, lifestyle risk factor management (i.e., 
exercise, diet, smoking), management of psychosocial health, medical risk factor management, 
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cardio-protective therapies, leisure time activities, outcomes assessment, and long-term 
management.
14
 In Ontario, CR is funded by the provincial health insurance program.
15
 
 In regards to accessing CR, patients are referred by a physician
1
. Once the referral is 
received, patients undergo an intake interview by program personnel
1
. This includes a medical 
assessment and exercise stress test to assess their suitability for exercise training, and to assign 
an appropriate exercise prescription. Patients then participate in group exercise classes about 1-3 
times per week on-site, and are taught to exercise safely on non-CR days at home
1
. Patients also 
participate in education sessions. At the end of the program, patients receive a repeat medical 
assessment: to update their exercise prescription, for recommendations to be made in regards to  
supporting the long-term management of their CVD, and to ensure they meet their risk factor 
treatment targets
1
. The median length of CR programs in Ontario is 5 months.
15
   
 Peer-reviewed scientific evidence, including randomized controlled trials, systematic 
reviews, and meta-analyses, have consistently established that patient participation in CR 
reduces mortality by approximately 25% when compared to usual care.
16
 The magnitude of the 
benefits achieved by participation in a CR program is comparable to that of other standard 
cardiac therapies, including statins,
16
 aspirin, and percutaneous coronary interventions (in low 
risk patients).
17
 Through the metabolic and physiological effects of exercise, promotion of 
medication adherence, smoking cessation, and improved nutrition and mental health, CR 
provides a comprehensive means of addressing a pathological atherosclerotic milieu which 
cannot be modified by surgical or percutaneous intervention alone.
18–20 
CR has also been shown 
to reduce the need for re-hospitalization, the use of interventional procedures, and to have 
beneficial effects on cardiac risk factors such as systolic blood pressure and total cholesterol.
21
 
CR participation can result in significant health behaviour changes such as increased exercise,
22
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improved diet, and smoking cessation
23
. CR is related to increased exercise capacity when 
compared to usual care.
24,25 
  
2.2 Quality and CR 
Cardiac care, including CR, is most effective if it is high-quality care. Care quality refers 
to a multidimensional construct that, as articulated by the Institute of Medicine,
26
 encompasses 
the concepts of safety, equity, evidence-based medicine, timeliness of care, efficiency, and 
patient-centeredness. Quality of care is defined as “the degree to which health services for 
individuals and populations increases the likelihood of desired health outcomes and are 
consistent with current professional knowledge.”26 The ability to quantify the quality of CR care 
critically depends on the translation of evidence-based recommendations into the measurement 
of that care. Without the ability to measure or quantify quality, and without the opportunity to 
identify practices that lead to higher-quality care, CR quality cannot be improved.  
QIs are intended to measure adherence to specific practice guidelines in order to reduce 
the gap between the evidence and actual clinical practice.
27
 QIs define the standard of care. They 
are used broadly to evaluate the quality of care locally or to compare between institutions, 
regions or countries, so as to support quality improvement. At the healthcare system level, they 
can be used to address performance by evaluating, for example, accessibility, safety, equity and 
efficiency. QIs can also be used to evaluate clinical aspects of care, namely the structure, 
processes and outcomes of cardiovascular secondary or tertiary care.
28
 
The impact of achieving quality improvement within Canadian CR programs has not 
been empirically established. However a recent study which computed the impact of using 
Coronary Heart Disease (CHD) QI benchmarks on mortality, found that the utilization of CR 
lowered mortality rates.
29
 Based on 2005 CR utilization rates post-MI in Ontario, if CR uptake 
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was increased to a 90% benchmark, 135 deaths could be prevented or postponed, with a 1.3% 
(95% CI, 1.0-1.6) reduction in CVD mortality. Thus, given that QIs are developed based on 
evidence of their impact on health outcomes, improving our attainment of CR QI benchmarks 
should similarly improve the health outcomes of Canadians.  
Among the first to develop QIs for CR was the American Association of Cardiovascular 
and Pulmonary Rehabilitation (AAVCPR), who developed a subtype of QIs, namely 
performance measures.
30
 These are specifically suitable for public reporting, external 
comparisons, and pay-for-performance.
30
 The European Association of Cardiovascular 
Prevention and Rehabilitation (EACPR) recently developed a QI on CR referral.
31
 Finally, a 
Dutch group in Europe also developed QIs.
32
 In Canada, CR QIs have recently been developed 
and are arguably the most rigorous and comprehensive fashion of all QIs internationally. The 
development of the Canadian CR QIs is described below. 
2.3 Development of Canadian CR QIs 
The Canadian Heart Health Strategy and Action Plan (CHHS-AP) provides an 
overarching framework for the future of the Canadian cardiac health system.
33
 Following 
recommendation by the CHHS-AP, an initiative was established by the CCS, with financial 
support from the Public Health Agency of Canada (PHAC), to develop pan-Canadian QIs for 
cardiovascular care.
34
 In 2011, the CCS Data Definitions and QI Steering Committee chose CR 
as the next chapter for QI development.  
A standardized methodology for QI development was developed, composed of 3 phases.
7
 
In phase 1, members representative of stakeholder organizations and experts in the field from 
across Canada were invited to serve on the working group. They created 5 sub-theme or domain 
groups, namely: (1) Referral, access, and wait times; (2) Secondary prevention, assessment, risk 
stratification, and control; (3) Behavioral change, program adherence, psychosocial issues, 
6 
 
education, and return-to-work; (4) CR model and structure; and (5) Discharge transition, linkage, 
and communication. These were populated with experts in the field, who were asked to develop 
candidate QIs in the structure, process and outcome dimensions of care, as described by 
Donabedian
28
. 
In phase 2, the working group considered candidate QI’s from existing Canadian1 and 
American
35
 sources – the latter being the only CR QI peer-reviewed publication identified by a 
2012 environmental scan prefacing this project.
33
 These and additional CR QIs suggested by the 
sub-theme groups underwent rapid review. Based on the summary of findings, 38 QIs was 
generated by the working group. 
Each CR QI was then drafted by the corresponding sub-theme group, with the following 
elements: name and definition, numerator, denominator (i.e., reference item or population, 
exclusions), sources of data, method of calculation, rationale, clinical recommendation(s) with 
corresponding guideline citations, and challenges to implementation. The CR QI working group 
provided the subgroups with input on the 38 preliminary CR QIs, which subsequently underwent 
formal expert panel rating. Eight indicators were removed from the list following the results of 
the ranking survey.  
With regard to the third phase, further external input was solicited. The 30 QIs were 
posted for a one-month web-consultation process on the CCS QI website. QI technical 
specifications were refined and standardized by a methodologist from the Canadian Institute of 
Health Information. Approvals were solicited and received from CCS and CACPR. Two out of 
the final list of 30 QIs were then field-tested.
36
 The 30 QIs were then published.
6
  
To date there is only one publication to our knowledge describing the quality of CR in 
Canada. Fourteen of the QIs were assessed, and wide variation in quality across the indicators 
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was observed. This was undertaken using the Canadian Cardiac Rehab Registry (CCRR). The 
CCRR is a web-based tool that captures 200 variables from CR participants, pre and post-
program. The tool allows CR program data stewards to enter data concurrently during the 
program or after patient discharge. Following the reconciling of each QI with CCRR data 
definitions, it was found that 14 out of the 30 QIs (46.7%) could be assessed within the CCRR. 
Five thousand four hundred and forty seven patient records collected from all 11 CR programs in 
the CCRR were utilized for analysis
8
  
All of the CR QIs are expressed as a percentage except for QI- 2b which measures wait 
time from referral to enrolment in median days. Results showed that wait times for enrollment 
grossly exceeded the 30-day QI target,
37
 with a median of 84 days. QIs that measured assessment 
of blood pressure and adiposity were high (90% and 85% respectively).
8
 However QIs that 
measured assessment for lipids (41%), blood glucose among diabetic patients (23%), and 
depression screening amongst patients (13%) were low.
8
 Only 68% of patients had achieved a 
half metabolic equivalent of task (MET) increase in exercise capacity at program discharge. Only 
61% of smokers were referred to smoking cessation therapy.
8
 Thirty percent of participants were 
offered stress management.
8
 Ninety percent of patients completed the CR program, however this 
was considered an over-estimation due to failure to enter non-participating patients into the 
Registry.
8
 Regardless, there are areas in which this inquiry suggests CR quality is poor and that 
further research is required. 
2.4 Objective 
 The objective of this study is to assess more CR QIs than has been done previously, and 
to investigate the variation in these QIs. The quality of 3 CR programs in the GTA will described 
using the recently published 30 Canadian CR QIs. Twenty-one out of 30 QIs have been deemed 
8 
 
assessable and will be described. Eleven of the QIs which will be assessed herein, including the 
structure QIs, have yet to be assessed (Table 1).To establish the level of criterion validity in this 
study, the QIs will be measured against corresponding self-report data. Four out of the 21 QIs 
can be tested for criterion validity. Thus this research will more fulsomely characterize CR 
quality, which is an essential first step before we can work towards improved CR delivery, 
outcomes and efficiency. 
2.5 Candidate’s Role  
 My primary role in this study was to coordinate the CR Program Evaluation database (for 
participants recruited during graduate training). This included managing the participant database 
in MS Excel, entry of patient chart data from Case Report Forms (CRFs) into the IBM SPSS 22
38
 
database, emailing out participant surveys online, following up with non-responding participants 
via phone and email according to a modified Dillman method
39
, data merging and cleaning, as 
well as Knowledge Transfer (KT).  Other study oversight included maintaining the study 
binders, ensuring secure storage of Informed Consent Forms (ICFs) and other source documents, 
as well as communication with Research Ethics Boards. I also performed all of the statistical 
analyses and writing for this research. 
3.0 METHODS 
3.1 Design  
A CR program evaluation cohort was utilized for this secondary analysis. This study was 
observational, and prospective in design. Approval from the research ethics review boards at 
each of the 3 CR sites as well as York University was received. Data from participants who were 
recruited into one of 3 CR programs between July 2010 and February 2014 were used in this 
study. Data from the first two assessment points (i.e., corresponding to CR intake and discharge 
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approximately 6 months later for those who stayed in the program) were analyzed for the 
purposes of this study.  
3.2 Setting 
 The cohort consisted of participant data collected from 3 CR sites in the Greater Toronto 
Area: the Toronto Western Hospital (Toronto), Mackenzie Health (Richmond Hill), and 
Southlake Regional Health Centre (Newmarket). Two of the CR programs were located adjacent 
to community hospitals within a suburban setting, while the third CR program was located 
within an academic hospital in an urban setting. All 3 programs offered CR in accordance with 
CACPR Guidelines.
1
 
Table 2 describes the attributes of each site. Each offered an initial group education 
session prior to an individual intake assessment. The program located in an academic hospital 
offered 90 minute twice-weekly classes, for a duration of 4 months. The community CR 
programs offered 60-90 minute twice-weekly classes, and one 90 minute weekly class, 
respectively, for 6 months. All three programs offered education classes, on-site exercise 
programs, dietary counselling for groups or individuals, smoking cessation referrals, and 
psychosocial assessment/support. In addition, the two community CR programs offered 
vocational counselling, spousal/family support, as well as stress management on an individual 
basis. All three programs offered morning and afternoon classes. However the community CR 
programs offered evening classes as well.  
With regard to cost, the CR program located within an academic setting is covered 
entirely by provincial healthcare, and is accessible by public transit. Parking at the site costs 
$4.50 per ½ hour visit and $9 per day. One of the community CR programs costs $55 plus tax 
10 
 
per month, while parking is free. The other community CR program is covered by provincial 
healthcare, however education materials costs $100, and parking is $3 per visit.  
3.3 Procedure 
At their first CR visit, all patients are approached to solicit informed consent by 
personnel involved in the circle of care (Appendix A). From study inception (July 2010) to 
February 2012, consenting patients were provided 2 copies of  the Informed Consent Form (ICF) 
with a stamped pre-addressed return envelope. Later on, in an effort to reduce costs, new patients 
were provided a study information sheet with instructions to email the study coordinator. Once 
the study coordinator received an email, the patient was sent a link to where the site-specific ICF 
was presented. Patients were asked to read through and check the box at the bottom to indicate 
consent.  
All patients completed an intake assessment as part of their standard care. This included 
risk factor assessment, an exercise stress test, and blood work (e.g., lipid panel, glycated 
hemoglobin or HbA1c). Some of this data, as well as some referral form information, was 
extracted onto the Case Report Form (CRF) (Appendix B). This assessment protocol was 
repeated at the end of CR for those who completed the program. CR charts for all consenting 
participants were audited at expected CR discharge to ascertain program participation and to 
record available discharge asssessment data  (Appendix C). 
Participants were also asked to complete a self-administered survey (relevant excerpts in 
Appendix D) in paper or online format, in accordance with the format through which they 
provided informed consent. The intake survey’s purpose was to describe the sample by assessing 
socio-demographic characteristics such as income, education, marital status and, ethno-cultural 
background through forced-choice items. Online surveys were administered using a secure web 
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survey program called “Survey Monkey”. These surveys were administered once consent was 
obtained, and hence they were generally completed by participants who had participated in initial 
CR sessions.  
A modified Dillman protocol
39
 was applied at all assessment points to optimize survey 
response rate. If after the survey was emailed the first time the participant did not respond within 
two weeks or had not clicked the “opt-out” button, a replacement survey would be emailed. If 
patients did not respond or click the “opt-out” button within the next two weeks, the patient 
would be called to ascertain whether they received the e-mail correspondence or if they had any 
questions. If the patient still had not completed the survey two weeks after the patient call, the 
patient would be considered a non-responder for that assessment. 
Two structure QIs was measured in this study: one measures whether the program has an 
emergency response strategy (QI-31; Appendix E), and the other whether the program has 
Medical Director supervision (QI-32; Appendix E). To assess these QIs, written program policies 
were audited and clinicians were interviewed at each of the 3 CR sites.  
3.4 Participants 
This convenience sample consisted of all consenting participants referred to the 3 CR 
programs. Four hundred and eleven participants consented to the study from all three programs 
(128 from Toronto Western Hospital, 99 from Southlake Regional Hospital, and 184 from 
Mackenzie Health). Participants were referred to the CR programs with the following cardiac 
diagnoses or procedures: acute coronary syndrome, chronic stable angina, or stable heart failure, 
as well as percutaneous coronary or valvular intervention, coronary artery bypass graft (CABG) 
± valve surgery, cardiac transplantation, or mild non-disabling stroke.
1
 The inclusion criterion 
was that participants were deemed eligible to complete CR following the intake assessment (i.e. 
12 
 
no co-morbidities identified or indications from the exercise stress test that would preclude CR 
participation). Participants who were not proficient in the English language were excluded from 
the study.  
3.5 Measures 
 Sociodemographic characteristics of the sample such as income, education, marital status, 
and ethno-cultural background were assessed through forced-choice items in the intake survey 
(Appendix D). Clinical measures were extracted from CR referral forms, as well as CR intake 
and discharge assessments, onto intake and discharge CRFs (Appendix B & C). This enabled 
description of the sample, including: previous cardiac diagnoses, referral and intake dates, 
referral indications, age, sex, comorbid conditions, cardiac medications, cardiac risk factors (e.g. 
lipids, blood pressure, blood glucose, Body Mass Index, and waist circumference), as well as 
program participation and completion. Peak Metabolic Equivalents of Task (METs) were 
obtained from the graded exercise stress tests. The level of change from intake to the discharge 
assessment was necessary to measure QI-17 or increase in exercise capacity (Table 3).  
Quality Indicators 
 Twenty-one out of the 30 CR QIs were assessable within the study: 10 process (QI-2a, 
2b, 3, 5, 13, 14, 15, 16, 26, 30), 9 outcome (QI-7, 8, 9, 10, 12, 17, 18, 24, 37), and 2 structure 
(Appendix E). Each process and outcome QI were assessed using the CR charts as outlined in 
Table 3. Seven of the QIs had established benchmarks to which performance could be 
compared.
40,41
  
The definitions of QIs 2a, 3, 26, and 30 were slightly modified due to what data was 
available. Specifically, QI-2a measured wait time from hospital discharge to enrollment in all 
participants, not just those who were eligible and were in-patients. For QI-3, the percentage of 
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participants who enrolled and underwent an intake assessment was captured, not who attended 
any first visit (as all participants had already attended an initial visit during which time they were 
invited to participate in the study). QIs- 26 and 30 captured patients who received, instead of 
were referred to, a smoking cessation or stress management intervention, respectively.  
In regards to the structure QIs, the strategy in place to enable prompt defibrilliation (e.g. 
accessible “crash cart”, automated external defibrillator, code blue policies), and current Basic 
Cardiac Life Support certification of all clinical staff, was reviewed for QI-31. For QI-32, 
medical director supervision was determined by reviewing the program’s organizational chart 
and the job description of the most senior physician, if available.  
3.6 Statistical Analyses 
 IBM SPSS version 22 was used.
38
 Sociodemographic and clinical characteristics of 
participants were computed and described. These were compared by site using analysis of 
variance (ANOVA) with post-hoc least significant differences (LSD) tests. A p-value of <0.05 
was defined as a significant difference between groups. 
Retention for the discharge assessment was calculated. The sociodemographic and 
clinical characteristics at intake of the retained and non-retained samples in terms of graduation 
from the program were compared using Chi-square and Student’s t-test analyses as applicable.  
For the first objective, each of the QIs were described. The values for each QI was 
computed in accordance with the definitions provided in Appendix E. The value for QI-2b was 
calculated in median days (Appendix E). Some QIs were assessed only in those who completed 
CR (i.e., QIs- 5, 7, 8, 9, 10, 12, 17, 18, 26, 30, 34, and 37 as per Table 3). The graduation status 
of the participant was obtained from the discharge CRF (Appendix C p2 q5).  To test the second 
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objective, ANOVA was utilized to analyze differences on each QI (dependent variable) by CR 
site (independent variable).   
4.0 RESULTS 
4.1 Respondent Characteristics  
 Of the participants approached, 411 consented. Figure 1 shows the participant flow 
diagram. Table 4 displays the pre-CR sociodemographic and clinical characteristics of the cohort 
by site. Participants significantly differed by marital status, racial /ethnic background, peak 
METs, CABG surgery as a referral indication, the risk factors dyslipidemia and hypertension, 
and medication use (i.e. Acetylsalicyclic Acid [ASA], statins, beta-blockers, anti-coagulants, and 
other cardiac medications).  
CR charts were available for 394 (96.1%) participants at post-test. Of these, 209 (53.0%) 
completed a discharge assessment, and were thus considered to have completed the program 
(Figure 1). Characteristics of those who graduated and those who did not, are shown in Table 5. 
Participants who completed CR were significantly less likely to have been referred due to 
arrhythmia, and more likely to have been prescribed ASA at discharge. No other differences 
were observed.  
4.2 CR Quality 
QI findings (percentages or median days for QI-2b) are displayed in Table 6.  Of the 7 
QIs for which there exists an established benchmark, quality for 2 (28.6%) of the indicators 
exceeded the benchmark (QIs 3 enrollment and 13 assessment of blood pressure).  
 For QIs without an established benchmark, performance was 75% or above for: 
participants who received education (QI-5), assessment of adiposity (QI-15), participants who 
received a stress management intervention (QI-30), programs with medical director oversight 
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(QI-32), programs with a documented emergency response strategy (QI-31), and communication 
with the primary healthcare provider at discharge (QI-34; i.e. discharge summary on file 
addressed to primary care). QIs for which performance was observed to be below 50% were (in 
ascending order): wait time from hospital discharge to enrollment (QI-2a), prescription of other 
anti-platelets at discharge (QI-8), and assessment of blood glucose control (QI-16; the latter has a 
benchmark). 
 Differences in CR quality by site are displayed in Table 7. QIs which had an insufficient 
sample size for analysis at the site level (i.e. less than 2 cases) were excluded. These indicators 
were: smoking cessation support (QI-26), programs with medical director oversight (QI-31), and 
programs with a documented emergency response strategy (QI-32). Thus, 17 (81.0%) QIs were 
analyzed. Significant differences in performance between sites were observed for 11 (64.7%) 
QIs. Exceptions were QIs- 2a, 3, 8, 12, 13, and 34. The magnitude of quality differences between 
sites was largest for assessment of lipid control (72.6%), followed by assessment of blood 
glucose control (69.0%), and wait time from referral to enrollment in median days (30.6 days). 
5.0 DISCUSSION 
 There are gaps between what we know to be effective CR care and the care we provide. 
Results of this study demonstrate that efforts are needed to improve CR quality in some areas, 
and that it varies considerably across programs. Quality was greatest for the 2 CR structure 
indicators, assessment of blood pressure control, communication with primary care, enrollment 
and patient education and was lowest for wait times, assessments of blood glucose, and lipid 
control. 
Quality in terms of wait-time from hospital discharge to enrollment was the lowest of all 
indicators assessed. Reduction in wait times could be achieved by targeting the referral stage. 
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Systematic strategies have proven to reduce wait times by ensuring patients are referred as 
inpatients prior to hospital discharge, not weeks later at an outpatient visit.
42,43
 Lack of capacity 
for new patients, or lack of human resources to process referrals received could also explain the 
unduly long wait times observed. The wait times observed are disconcerting, given emerging 
evidence of the negative impact of prolonged waits on many outcomes from cardiac remodeling 
to program enrollment.
43,44
  
Program completion could be improved, given that a dose-response association exists between 
CR adherence and mortality.
45
 Interventions to improve CR adherence have been recently 
reviewed.
46
 Of the 8 trials identified, only 3 had a significant effect in increasing adherence. 
These interventions included self-monitoring of activity, action planning and tailored counselling 
by CR staff. Although the root causes of low CR adherence are multifactorial and complex, these 
interventions could be applied to optimize patient outcomes. Low assessment of blood 
glucose and lipids may be explained in that CR staff aim to avoid duplicate testing to save costs 
to the health care system. These tests may have already been completed by another of the 
patients’ healthcare providers. This could be overcome where electronic medical records could 
be shared between specialist, generalist and CR providers to ensure programs have access to 
such results. Alternatively, the patients may have reported that they do not have diabetes, or staff 
may have observed that their lipids were well-controlled pharmacologically. 
Cardiac medication use post-CR was surprisingly low. Given individual indications and 
contraindications were not taken into consideration in this study, the prescription of certain drugs 
may not have been appropriate for all patients (e.g., in post-myocardial infarction patients only 
those with poor left ventricular function and heart failure are indicated for a beta-blocker). The 
data was recorded from program charts, and likely reflects patient report to CR staff of 
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medications taken, as medication prescription is usually undertaken by a patient’s specialist 
rather than these CR programs. It is hoped that the post-program communication from the CR 
program to the patients’ primary care provider (which was frequent) lists their medications and 
recommendations for medication additions and changes in accordance with guidelines.  
Upon comparison of the QI findings from this study to those obtained from the Canadian 
Cardiac Rehab Registry (CCRR),
8
 similarities and differences were observed. Indicators that 
were fairly consistent in the CCRR and in this study, respectively, were: QI-13 assessment of 
blood pressure control (90% versus 98%), QI-15 assessment of adiposity (85% versus 88%), QI-
17 increase in exercise capacity (69% versus 68%), and QI-16 assessment of lipid control (41% 
versus 42%). Inconsistencies were seen in some indicators as well. Assessment of blood glucose 
was about half the rate in the CCRR as was observed herein (23% vs. 42%).  
 This study was the first to examine QI differences between CR sites. For approximately 
two-thirds of the QIs, significant site differences were observed. These findings are worrisome, 
as they suggest that some of the sites are providing much lower quality care than their 
counterparts. Differences may have arisen from variation in levels of resources or staff 
complement at each program, and in provider practice. Another explanatory factor could be the 
lack of standardization in charts and charting practices across the CR sites. Site differences in 
delivery of care could have negative repercussions for the outcomes of patients who are referred 
to one CR program over another for reasons such as geographic location. However as the results 
showed, patients differed significantly between sites in terms of their sociodemographic and 
clinical characteristics at intake. Thus this likely also contributed to the site differences in quality 
observed. 
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 Improvement initiatives are needed to increase quality where it was low, and also to 
reduce CR site variation. Indeed, some organizations have developed CR standards
31,47
 which, 
where implemented, may reduce variability. Moreover, a recent American study demonstrated 
how a series of quality improvement activities, namely program policy changes as well as patient 
educational materials and incentives, significantly improved CR program session attendance 
among graduating patients.
24
 CR programs could also form a “community of practice” to share 
best practices enacted by high-performing programs with lower-performing ones. 
5.1 Limitations 
Caution is warranted when interpreting the findings. First, the representativeness of the 
cohort is unknown, as the CR sites did not record which patients were approached to participate 
but declined. As well, consenting patients may have had particular psychological characteristics, 
such as high motivation and perseverance, that set them apart from patients who did not, and this 
could have affected the results. Thus, selection bias may be at play. More broadly, the majority 
of cardiac patients indicated for CR are not referred, and hence the findings will only be 
generalizable to those who are referred and ultimately attend an initial CR session. 
Second, the generalizability of the findings for the 14 QIs which required CR discharge 
data is not known, considering only half of the patients completed the program. The retained 
cohort did not differ greatly from those lost to follow-up however. Nevertheless, these QIs 
should be interpreted with caution as they may be under or over-inflated.  
Third, due to the use of secondary analysis, there was an inability to assess all of the QI 
exclusions spelled out by the CCS (see Table 11), and to establish the criterion validity of all 22 
QIs analyzed. QI-2b, however, which was not analyzed for criterion validity in this study has 
been field-tested previously demonstrating high validity.
49
 Therefore, some of the findings 
should be interpreted with caution.  
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Fourth, the sample size was very small for the structure QIs, and hence these findings 
should not be over-interpreted. Finally, the generalizability of the study results to other CR 
programs is unknown, particularly to CR programs with differing payment models, and location 
(e.g. rural).  
6.0 EXTENDED METHODS 
 
 Given the newness of the Canadian CR QIs, the criterion validity of the QIs was 
assessed. Based on available data, there were 4 (19.0%; QIs- 2a, 3, 17, and 18) QIs that could be 
assessed for validity as outlined in Table 8. The criterion validity of each was tested by assessing 
the association of chart with self-report data from the discharge surveys. The discharge survey 
included many of the same measures in the intake survey to assess change.  This survey was 
adminstered 6 months following intake (relevant excerpts in Appendix F). These were sent 
independent of the CR programs, such that participants would be willing to complete them 
regardless of whether or not they completed the program. The validity of 3 of the QIs (2a, 3, and 
18) were tested with investigator-generated items. 
With regard to QI-17, the survey also included the Duke Activity Status Index (DASI,
50
; 
see Appendix F, section A), which is a 12-item scale, where patients are asked about activities of 
daily living. Scores can be converted to METs, with higher scores denoting greater functional 
capacity. 
 Cohen’s kappa and Pearson’s correlation analyses were employed as appropriate to 
determine the magnitude of the relationship between chart and self-report data. Pearson’s 
Correlation analysis was also used to determine the relationship between wait time (in days) 
indicated in the discharge surveys versus chart data (QI-2a), as well as change in METs 
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measured in both discharge surveys and charts (QI-17). Kappa coefficients were interpreted in 
accordance with established guidance
51
 as follows: less than 0 to indicate no agreement, 0-0.20 
as slight, 0.21-0.4 as fair, 0.41-0.6 as moderate, 0.61-0.80 as substantial, and 0.81-1 as almost 
perfect agreement. A correlation coefficient of 0.30 was the minimum value to indicate a 
relationship. 
7.0 EXTENDED RESULTS 
Two-hundred and forty-four (59.4%) participants completed the discharge survey. Values 
for QIs 2a, 3, 17 & 18 which were ascertained using chart (criterion) versus self-report are shown 
in Table 9. The criterion validity results are shown in Table 10. Cohen’s kappa analysis showed 
that there was slight agreement for QI-17, and fair agreement for QIs-2a and 3. Pearson’s 
correlation analysis for QI-18 revealed a coefficient well under 0.30, indicating lack of 
agreement and hence lack of validity. Pearson’s correlation analyses revealed that there was no 
relationship between self-reported wait time and wait time indicated in charts (in days) (r=-0.02), 
and between change in METs ascertained through the DASI questionnaire and peak METs 
indicated in charts (r=0.09). 
8.0 EXTENDED DISCUSSION 
 No to fair QI validity was observed. The lack of high validity in the QIs assessed could 
have been due to the poor reliability of the investigator-generated items utilized (relevant to QIs 
2a, 3, and 18). However, the absence of criterion validity for QI 18 was in contrast to findings 
from a past study which demonstrated high validity between self-report and chart data for 
adherence to program sessions.
52
 Perhaps, patients may not have been able to accurately recall 
the percentage of classes that they had attended when completing their discharge survey. In 
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terms of QI-17, DASI scores are a highly correlated measure of functional capacity.
50
 However it 
has been found that patient responses to DASI questions often under or over-estimate their 
exercise capacity in comparison to what would have been measured clinically.
53,54
 A primary 
study specifically designed to test QI validity is needed before definitive conclusions can be 
drawn. 
9.0 KNOWLEDGE TRANSLATION 
 Knowledge translation or KT is defined by the Canadian Institute of Health Research as 
“a dynamic and iterative process that includes the synthesis, dissemination, exchange and 
ethically sound application of knowledge to improve health, provide more effective health 
services and products, and strengthen the health care system”.55 Given the applied nature of this 
study, it was determined that programs would benefit from learning of the areas where the QIs 
were valid and poor or variable quality was observed.  
Thus, as part of the KT process, each CR site was emailed with an offer of a site-specific 
presentation of the findings. I developed a confidential site-specific presentation for the 1 
program which responded. The presentation compared the site’s QI findings to the aggregate of 
those of the other 2 sites. The site was informed as to where, in terms of quality, it was 
performing well and where improvement was required.  
I was also able to contribute to KT as a member of the CCRR Research and Program 
Liaison sub-committees. The Research sub-committee established the CCRR minimum data set 
based on the CR QIs. The QIs were also integrated into the quarterly progress reports for 
programs. The program liaison sub-committee trains programs entering data into the CCRR, and 
provides them with their progress reports. In the near future, TWH and Southlake will receive 
information on their quality in this manner.  
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 In terms of academic KT, I have presented my research findings at the 2014 Toronto 
General Research Institute Research day,
56
 and will be presenting at the 2015 American 
Psychology Association convention in Toronto. A manuscript of the research findings was 
recently submitted to the Journal of Cardiopulmonary Rehabilitation and Prevention, and is 
currently under review.  
10.0 DIRECTIONS FOR FUTURE RESEARCH  
In addition to translating knowledge from these findings into practice at the participating 
programs and beyond, there are several key directions for future research stemming from this 
thesis. First, given the low validity observed for the QIs which could be assessed, refinement of 
these QIs is warranted. Assessment of the validity of the other QIs is also imperative.  
 Second, the following QIs have yet to be assessed in any study to our knowledge: QIs 1, 
20, 21, 35, and 36. In future, assessment of these should be undertaken within a consecutive 
sample of patients to ensure generalizability, in a random selection of programs nationally. 
11.0 CONCLUSION 
In conclusion, areas of high and low quality within GTA CR programs were identified 
using a higher number of CCS CR QIs than what was assessed in the past. As well for the first 
time, program differences were measured and observed in about half of the QIs tested. Methods 
that could be employed to increase quality in lacking areas, and to minimize site differences 
include: the use of systematic referral, use of electronic patient records across the continuum of 
care, and better inter-provider communication regarding use of evidence-based cardiac 
medications. Given the low validity found within the sub-set of QIs assessed, a primary study is 
warranted to fulsomely assess their validity and possibly refine the QIs.  
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KT initiatives underway have ensured that programs involved in this study and those 
reporting to the CCRR receive ongoing feedback on their quality, giving them evidence from 
which they can take steps towards improving their CR delivery. Given the recent integration of 
the QIs into the CCRR data definitions, recruiting as many CR programs as possible into the 
CCRR may facilitate standardization of CR care on a national scale.  
  
24 
 
12.0 REFERENCES 
1.  Stone JA, Suskin N, Arthur HM, et al. Canadian guidelines for cardiac rehabilitation and 
cardiovascular disease prevention: Translating knowledge into action. 3rd ed. (Stone JA, 
ed.). Winnipeg, Manitoba, Canada: Canadian Association of Cardiac Rehabilitation; 2009. 
2.  Heran BS, Chen JM, Ebrahim S, et al. Exercise-based cardiac rehabilitation for coronary 
heart disease. Cochrane database Syst Rev. 2011;(7):CD001800. 
3.  Smith SC, Feldman TE, Hirshfeld JW, et al. ACC/AHA/SCAI 2005 guideline update for 
percutaneous coronary intervention: a report of the American College of 
Cardiology/American Heart Association Task Force on Practice Guidelines 
(ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percut. J Am 
Coll Cardiol. 2006;47(1):e1–121. doi:10.1016/j.jacc.2005.12.001. 
4.  Nallamothu BK, Tsai TT, Tu J V. Implementing Evidence-Based Medicine in Cardiology. 
In: Yusuf S, Cairns AJ, Fallen EL, Gersh BJ, eds. Evidence-Based Cardiology.Vol 3. 3rd 
ed. Oxford, UK: Wiley-Blackwell; 2010:63–78. doi:10.1002/9781444309768.ch6. 
5.  Davis D, Evans M, Jadad A, et al. The case for knowledge translation: shortening the 
journey from evidence to effect. BMJ. 2003;327(7405):33–35. 
doi:10.1136/bmj.327.7405.33. 
6.  Grace SL, Poirier P, Norris CM, Oakes GH, Somanader DS, Suskin N. Pan-Canadian 
development of cardiac rehabilitation and secondary prevention quality indicators. Can J 
Cardiol. 2014;30(8):945–948. 
7.  Tu J V, Abrahamyan L, Donovan LR, Boom N. Best practices for developing 
cardiovascular quality indicators. Can J Cardiol. 2013;29(11):1516–1519. 
doi:10.1016/j.cjca.2013.05.012. 
8.  Grace SL, Parsons TL, Duhamel TA, Somanader DS, Suskin N. The Quality of Cardiac 
Rehabilitation in Canada: A Report of the Canadian Cardiac Rehab Registry. Can J 
Cardiol. 2014;30(11):1452–1455. doi:10.1016/j.cjca.2014.06.016. 
9.  Mendis S, Puska P, Norrving B. Global Atlas on cardiovascular disease prevention and 
control. (Mendis S, Puska P, Norrving B, eds.). Geneva, Switzerland: World Health 
Organization; 2011. Available at: 
http://whqlibdoc.who.int/publications/2011/9789241564373_eng.pdf. 
10.  Pilote L, Dasgupta K, Guru V, et al. A comprehensive view of sex-specific issues related 
to cardiovascular disease. CMAJ. 2007;176(6):S1–44. doi:10.1503/cmaj.051455. 
11.  Manuel DG, Leung M, Nguyen K, Tanuseputro P, Johansen H. Burden of Cardiovascular 
Disease in Canada. Tu J V, Ghali WA, Pilote L, Brien S, eds. Can J Cardiol. 
2003;19(9):997–1004. 
25 
 
12.  CHHS-AP Steering Committee. The Canadian Heart Health Strategy and Action Plan: 
Building a Heart Healthy Canada. Ottawa, ON: Submitted to the Minister of Health; 
2009. Available at: http://www.waittimealliance.ca/wp-content/uploads/2014/05/CCS-
Building-a-Heart-Healthy-Canada.pdf. 
13.  Manuel DG, Leung M, Nguyen K, Tanuseputro P, Johansen H. Burden of cardiovascular 
disease in Canada. In: Tu J V, Ghali WA, Pilote L, Brien S, eds. Canadian 
Cardiovascular Atlas. Toronto, ON: Pulsus Group Inc and the Institute for Clinical 
Evaluative Sciences; 2006:15–22. Available at: 
http://www.nlcahr.mun.ca/news/documents/reports/CCORT-Atlas_pt_1.pdf. 
14.  Buckley JP, Furze G, Doherty P, et al. BACPR scientific statement: British standards and 
core components for cardiovascular disease prevention and rehabilitation. Heart. 
2013;99(15):1069–71. doi:10.1136/heartjnl-2012-303460. 
15.  Polyzotis P, Tan Y, Prior PL, et al. Cardiac rehabilitation services in Ontario: components, 
models and underserved groups. J Cardiovasc Med. 2012;13(11):727–734. 
doi:10.2459/JCM.0b013e32835794c1. 
16.  LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-
analysis of randomized controlled trials. JAMA. 1999;282(24):2340–2346. 
17.  Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI 
for stable coronary disease. N Engl J Med. 2007;356(15):1503–1516. 
doi:10.1056/NEJMoa070829. 
18.  Wenger NK. Current status of cardiac rehabilitation. J Am Coll Cardiol. 
2008;51(17):1619–1631. 
19.  Chow CK, Jolly S, Rao-Melacini P, Fox KAA, Anand SS, Yusuf S. Association of diet, 
exercise, and smoking modification with risk of early cardiovascular events after acute 
coronary syndromes. Circulation. 2010;121(6):750–758. 
doi:10.1161/CIRCULATIONAHA.109.891523. 
20.  Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary 
prevention programs for patients with coronary artery disease. Ann Intern Med. 
2005;143(9):659–672. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16263889. 
Accessed August 12, 2011. 
21.  Miller TD, Balady GJ, Fletcher GF. Exercise and its role in the prevention and 
rehabilitation of cardiovascular disease. Ann Behav Med. 1997;19(3):220–229. 
22.  Grace SL, Grewal K, Arthur HM, Abramson BL, Stewart DE. A prospective, controlled 
multisite study of psychosocial and behavioral change following women’s cardiac 
rehabilitation participation. J Womens Health (Larchmt). 2008;17(2):241–248. 
26 
 
23.  Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart 
disease. Cochrane database Syst Rev. 2004;1(1):CD003041. 
doi:10.1002/14651858.CD003041.pub2. 
24.  Maines TY, Lavie CJ, Milani R V, Cassidy MM, Gilliland YE, Murgo JP. Effects of 
cardiac rehabilitation and exercise programs on exercise capacity, coronary risk factors, 
behavior, and quality of life in patients with coronary artery disease. South Med J. 
1997;90(1):43–49. 
25.  Vanhees L, Fagard R, Thijs L, Amery A. Prognostic value of training-induced change in 
peak exercise capacity in patients with myocardial infarcts and patients with coronary 
bypass surgery. Am J Cardiol. 1995;76(14):1014–1019. 
26.  Institute of Medicine. Crossing the Quality Chasm: A New Health System for the 21st 
Century. Washington, D.C.: National Academy Press; 2001. 
27.  Tu J V, Khalid L, Donovan LR, Ko DT. Indicators of quality of care for patients with 
acute myocardial infarction. CMAJ. 2008;179(9):909–915. doi:10.1503/cmaj.080749. 
28.  Donabedian A. Quality assessment and assurance: unity of purpose, diversity of means. 
Inquiry. 1988;25(1):173–192. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/2966122. Accessed September 10, 2012. 
29.  Wijeysundera HC, Mitsakakis N, Witteman W, et al. Achieving Quality Indicator 
Benchmarks and Potential Impact on Coronary Heart Disease Mortality. Can J Cardiol. 
2011;27:756 –762. doi:10.1016/j.cjca.2011.06.005. 
30.  Thomas RJ, King M, Lui K, Oldridge N, Piña IL, Spertus J. AACVPR/ACC/AHA 2007 
performance measures on cardiac rehabilitation for referral to and delivery of cardiac 
rehabilitation/secondary prevention services. J Cardiopulm Rehabil Prev. 
2007;27(5):260–290. doi:10.1097/01.HCR.0000291295.24776.7b. 
31.  Piepoli MF, Corrà U, Adamopoulos S, et al. Secondary prevention in the clinical 
management of patients with cardiovascular diseases. Core components, standards and 
outcome measures for referral and delivery: A Policy Statement from the Cardiac 
Rehabilitation Section of the European Association for. Eur J Prev Cardiol. 
2012;21(6):664–681. doi:10.1177/2047487312449597. 
32.  Van Engen-Verheul M, Kemps H, Kraaijenhagen R, De Keizer N, Peek N, Van Engen-
Verheul, Mariette; Kemps, Hareld; Kraaijenhagen, Roderik; De Keizer, Nicolette; Peek N. 
Modified Rand method to derive quality indicators: a case study in cardiac rehabilitation. 
Stud Health Technol Inform. 2011;169:88–92. doi:10.3233/978-1-60750-806-9-88. 
33.  Abrahamyan L, Boom N, Donovan LR, Tu J V. An international environmental scan of 
quality indicators for cardiovascular care. Can J Cardiol. 2012;28(1):110–118. 
doi:10.1016/j.cjca.2011.09.019. 
27 
 
34.  Kerr CR. Benefits and expected outcomes of the Pan-Canadian Data Definitions and 
Quality Indicators projects. Can J Cardiol. 2010;26(8):405–406. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2954531&tool=pmcentrez&re
ndertype=abstract. Accessed November 1, 2012. 
35.  Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007 performance measures on 
cardiac rehabilitation for referral to and delivery of cardiac rehabilitation/secondary 
prevention services. J Am Coll Cardiol. 2007;50(14):1400–1433. 
36.  Grace, S.L., Tan, Y., Oh, P., Aggarwal, S., Unsworth, K., & Suskin N. Feasibility of 
assessing two cardiac rehabilitation quality indicators. J Cardiopulm Rehabil Prev. 2015. 
37.  Dafoe W, Arthur H, Stokes H, Morrin L, Beaton L. Universal access: but when? Treating 
the right patient at the right time: access to cardiac rehabilitation. Can J Cardiol. 
2006;22(11):905–911. Available at: 
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2570237&tool=pmcentrez&re
ndertype=abstract. Accessed August 10, 2011. 
38.  IBM Corp. IBM SPSS Statistics for Windows: Version 22.0. 2013. 
39.  Dillman DA. Mail and internet surveys: The tailored design method. New York: John 
Wiley; 2000. 
40.  Grace SL, Chessex C, Arthur H, et al. Systematizing inpatient referral to cardiac 
rehabilitation 2010: Canadian Association of Cardiac Rehabilitation and Canadian 
Cardiovascular Society joint position paper endorsed by the Cardiac Care Network of 
Ontario. Can J Cardiol. 2011;27(2):192–199. doi:10.1016/j.cjca.2010.12.007. 
41.  Wijeysundera HC, Mitsakakis N, Witteman W, et al. Achieving Quality Indicator 
Benchmarks and Potential Impact on Coronary Heart Disease Mortality. Can J Cardiol. 
2011;27(6):756–762. doi:10.1016/j.cjca.2011.06.005. 
42.  Grace SL, Scholey P, Suskin N, et al. A prospective comparison of cardiac rehabilitation 
enrollment following automatic vs usual referral. J Rehabil Med. 2007;39(3):239–45. 
doi:10.2340/16501977-0046. 
43.  Russell KL, Holloway TM, Brum M, Caruso V, Chessex C, Grace SL. Cardiac 
rehabilitation wait times: effect on enrollment. J Cardiopulm Rehabil Prev. 
2011;31(6):373–377. doi:10.1097/HCR.0b013e318228a32f. 
44.  Collins, C., Suskin, N., Aggarwal, S., & Grace S. Cardiac rehabilitation wait times and 
relation to patient outcomes. Eur J Phys Med Rehabil. 2014;Epub. 
45.  Martin B-J, Hauer T, Arena R, et al. Cardiac rehabilitation attendance and outcomes in 
coronary artery disease patients. Circulation. 2012;126(6):677–687. 
doi:10.1161/CIRCULATIONAHA.111.066738. 
28 
 
46.  Karmali KN, Davies P, Taylor F, Beswick A, Martin N, Ebrahim S. Promoting patient 
uptake and adherence in cardiac rehabilitation. Cochrane database Syst Rev. 
2014;6:CD007131. doi:10.1002/14651858.CD007131.pub3. 
47.  Cardiac Care Network of Ontario. Standards for the Provision of Cardiovascular 
Rehabilitation in Ontario.; 2014. 
48.  Pack QR, Johnson LL, Barr LM, et al. Improving cardiac rehabilitation attendance and 
completion through quality improvement activities and a motivational program. J 
Cardiopulm Rehabil Prev. 2013;33(3):153–159. doi:10.1097/HCR.0b013e31828db386. 
49.  SL G. Final Report: Cardiac Rehabilitation / Secondary Prevention Quality Indicator 
Pilot Field-Test.; 2013. 
50.  Hlatky MA, Boineau RE, Higginbotham MB, et al. A brief self-administered 
questionnaire to determine functional capacity (the Duke Activity Status Index). Am J 
Cardiol. 1989;64(10):651–654. doi:10.1016/0002-9149(89)90496-7. 
51.  Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam 
Med. 2005;37(5):360–3. Available at: http://www.ncbi.nlm.nih.gov/pubmed/15883903. 
Accessed February 2, 2015. 
52.  Kayaniyil S, Leung YW, Suskin N, Stewart DE, Grace SL. Concordance of self and 
program-reported rates of cardiac rehabilitation referral, enrollment and participation. 
Present Can Assoc Heal Serv Policy Res Conf. 2009;25(4):e96–9. Available at: 
http://www.ncbi.nlm.nih.gov/pubmed/19340365. 
53.  Dunagan J, Adams J, Cheng D. Development and evaluation of a treadmill-based exercise 
tolerance test in cardiac rehabilitation. Proc (Baylor …. 2013;26(2):247–251. Available at: 
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3684288/. 
54.  Tang WHW, Topol EJ, Fan Y, et al. Prognostic Value of Estimated Functional Capacity 
Incremental to Cardiac Biomarkers in Stable Cardiac Patients. J Am Heart Assoc. 
2014;3(5):e000960–e000960. doi:10.1161/JAHA.114.000960. 
55.  Canadian Institutes of Health Research. More About Knowledge Translation at CIHR. 
2014. Available at: http://www.cihr-irsc.gc.ca/e/39033.html 
56.  Somanader, D.S., Tan, Y., Chessex, C., Fair, T., & Grace S. Quality of cardiac 
rehabilitation programs in the Greater Toronto Area. 2014. 
57.  Grace SL, Leung YW, Reid R, et al. The role of systematic inpatient cardiac rehabilitation 
referral in increasing equitable access and utilization. J Cardiopulm Rehabil Prev. 
2012;32(1):41–7. doi:10.1097/HCR.0b013e31823be13b.  
  
29 
 
Figure 1: Patient Flow Diagram 
  
Patients who consented at 
initial CR visit 
N=411 
Site 1=128 (31.1%) 
Site 2=99 (24.1%) 
Site 3=184 (44.8%) 
 
Patients completed intake 
survey 
n=321 (78.3%) 
Site 1=84 (66.1%) 
Site 2=89 (89.9%) 
Site 3=148 (80.4%) 
Patients completed intake 
assessment  
n=401 (97.8%) 
Site 1=125 (98.4%) 
Site 2=98 (99.0%) 
Site 3=178 (96.7%) 
 
 
 
 
n 
After 6 mo patients complete 
discharge survey 
n=244 (59.5%) 
Site 1=62 (25.4%) 
Site 2=64 (26.2%) 
Site 3=118 (48.4%) 
 
Patients completed CR discharge 
assessment and graduated  
 
n=209 (53.0%) 
 
Site 1=75 (35.9%) 
Site 2=59 (28.2%) 
Site 3=75 (35.9%)  
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Table 1: Canadian Cardiovascular Society Cardiac Rehabilitation and Secondary Prevention 
Quality Indicators assessed in the Canadian Cardiac Rehabilitation Registry vs. this study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CR= Cardiac Rehabilitation; ACEi= Angiotensin Converting Enzyme Inhibitors;  
ARB=Angiontensin II Receptor Blockers; BP= Blood Pressure; HbA1c= Glycated hemoglobin  
QI# QI name 
Assessed 
previously 
in CCRR 
(14) 
Assessed in 
Thesis 
(21) 
1 In-patients referred to a CR Program     
2a CR Wait time from hospital discharge   x 
2b CR Wait time from referral to enrolment x x 
3 CR Enrolment x x 
4 Risk Assessment for adverse CR events x   
5 Patient self-management education   x 
7 
Secondary Prevention medications: 
Acetylsalicyclic Acid (ASA) 
  x 
8 
Secondary prevention medications: Anti-platelet 
agents other than ASA  
  x 
9 
Secondary prevention medications: Beta 
Blockers  
  x 
10 Secondary prevention medications: Statins    x 
12 Secondary prevention medications: ACEi/ARB    x 
13 Assessment of BP control  x x 
14 Assessment of lipid control  x x 
15 Assessment of adiposity x x 
16 
Individual assessment of blood glucose control 
(HbA1c) 
x x 
17 Increase in exercise capacity x x 
18 Adherence to CR program   x 
20 Meeting physical activity guideline      
21 Promotion of post-CR physical activity    x 
22 Assessment of depression  x  
23 
Referral of patients screening positive for 
possible depression 
x  
26 Smoking cessation support x x 
27 Smoking cessation x 
 
30 Stress management x x 
31 Medical director supervision   x 
32 Emergency response strategy   x 
34 
Communication with the primary health care 
practitioner 
  x 
35 Recommended elements in discharge summary     
36 Summative communication with patient     
37 CR program completion x x 
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Table 2: Attributes of CR Sites studied 
 
 Site Name 
 TWH SRHC MH 
Duration (months) 4 6 6 
Annual volume 400 700 550 
Academic vs. 
Community 
Academic Community Community 
Frequency of 
sessions per week 
2 1 2 
Automatic inpatient 
referral 
Yes Yes No 
Costs Free Free (educational 
materials cost $100) 
$55+HST/month 
 
TWH= Toronto Western Hospital 
SRHC= Southlake Regional Health Centre 
MH= Mackenzie Health  
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Table 3: Description of Where each QI is Assessed Within the Study Documents 
 
QI QI Name Where? Details 
2a
† 
 
CR Wait time from 
hospital discharge 
 
CRF1 
 
p2 q4 input discharge date  
p2 q5 input Date CR Referral received 
;created syntax to subtract dates 
 
2b 
CR Wait time from 
referral to enrolment 
CRF1 
p2 q5 Date CR Referral received  
p2 q6 Date of CR Intake Appointment 
;created syntax to subtract dates 
 
3
†
 CR Enrolment CRF1 
p2 q6: Date of Intake Appointment 
;if date was present then patient attended 
intake appointment 
5
†
 
Patient self-
management education CRF2 
p2 q1: Program elements utilized by patient 
(tick all that apply) 
7
†
 
Secondary Prevention 
medications: 
Acetylsalicyclic Acid  CRF2 
p3 q4: Medications at discharge (check all that 
apply) 
8
†
 
Secondary prevention 
medications: Anti-
platelet agents other 
than ASA  
CRF2 p3 q4: Medications at discharge (check all that 
apply) 
9
†
 
Secondary prevention 
medications: Beta 
Blockers  CRF2 
p3 q4: Medications at discharge (check all that 
apply) 
10
†
 
Secondary prevention 
medications: Statins  CRF2 
p 3 q4: Medications at discharge (check all 
that apply) 
12
†
 
Secondary prevention 
medications: 
ACEi/ARB  CRF2 
p3 q4: Medications at discharge (check all that 
apply) 
13 
Assessment of BP 
control  CRF1 
p3 q7: Risk Factors- Hypertension (Systolic 
and Diastolic BP)  
14 
Assessment of lipid 
control  CRF1 
p3 q7: Risk Factors- Dyslipidemia (Total 
cholesterol, HDL, LDL, triglycerides) 
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15 Assessment of adiposity CRF1 
p3 q7: Risk Factors- Obesity (BMI OR waist 
circumference) 
16 
Assessment of blood 
glucose control 
(HbA1C) CRF1 
p3 q7: Risk Factors- Diabetes (HbA1c%) only 
in those who have diabetes 
17
*
 
Increase in exercise 
capacity 
CRF1/CRF2 
CRF1: p4 q15b- Peak METs at intake 
CRF2: p3 q2c- Peak METs at discharge 
;created syntax to count patients who had 
increased capacity by ½ of intake MET by 
discharge 
18 
Adherence to CR 
program CRF2 
p2 q2-3 Number of sessions prescribed and 
number of sessions completed; calculated 
percentage 
26
†
 
Smoking cessation 
support CRF2 
p2 q1 – Program elements utilized by patient 
(tick all that apply) 
30
†
 Stress management CRF2 
p2 q1 – Program elements utilized by patient 
(tick all that apply) 
31 
Medical director 
supervision 
policy from 
site 
Reviewed organization chart and job 
description of senior physician  
32 
Emergency response 
strategy audit at site 
Reviewed BLS certification of clinical staff 
and emergency strategy 
34
†
 
Communication with 
the primary health care 
practitioner 
CRF2 
p3 q3- Chart Indication discharge report 
mailed to PCHP?- Yes/No 
37
†
 CR program completion CRF2 
p2 q5- Did patient complete the program? -
Yes/No 
 
CRF=Case Report Form  
p=page 
q= question 
BMI= Body Mass Index 
HbA1c= Glycated Hemoglobin 
HDL=High Density Lipoprotein 
LDL=Low Density Lipoprotein 
MET=Metabolic Equivalent of Task 
PCHP=Primary Care Health Care Provider 
†Quality Indicators measured at discharge 
*Quality Indicators measured at intake and discharge
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Table 4: Pre-CR Sociodemographic and Clinical Characteristics of Participants by CR Site 
 
Characteristic  
Site 1 
(n=128, 31.1%) 
Site 2 
(n=99, 24.1%) 
Site 3 
(n=184, 44.8%) 
p 
Sociodemographic      
Age (mean±SD years)†  64.2±10.9 65.8±10.4 63.9±10.1 0.33 
Sex (% male)† 84 (67.2) 69 (69.7) 133 (72.3) 0.63 
Marital status (% married)    52 (40.6)
†††§§§
   68 (68.7)
†††
    116 (63.0)
§§§
 <0.001 
Education (% university or higher) 63 (49.2) 55 (55.6) 99 (53.8) 0.60 
Racial / Ethnic background, (% 
North American)  
38 (29.7)
††
   48 (48.5)
††§§§
 40 (21.7)
§§§
 <0.001 
Work status (% retired)  36 (28.1) 42 (42.4) 67 (36.4) 0.08 
Clinical†     
Previous cardiac diagnosis (% 
yes) 
14 (10.9) 13 (13.1) 12 (6.5) 0.16 
Peak METs§ (mean±SD) 7.8±3.2
††
 6.5±2.9
††
 7.1±2.7 0.007 
Referral Indication (% yes)     
Percutaneous Coronary 
Intervention 
53 (44.9) 42 (45.2) 58 (33.5) 0.07 
Coronary Artery Disease 41 (34.7) 21 (23.1) 65 (37.6) 0.06 
Myocardial Infarction 23 (19.5) 25 (27.2) 52 (30.2) 0.12 
Coronary Artery Bypass 
Graft Surgery 
20 (16.9)
†§§
 30 (33.0)
†
 59 (33.9)
§§
 0.004 
Arrhythmia 11(9.3)   7 (7.8) 18 (10.5) 0.78 
Other  17 (13.3) 11 (11.1) 25 (13.6) 0.83 
Risk Factors (% yes)     
Dyslipidemia   85 (80.2)
†††∆∆  46 (58.2)
†††§§§
 162 (95.3)
§§§∆∆ <0.001 
Hypertension    69 (60.5)
†††§§§
   76 (82.6)
†††
 145 (84.8)
§§§
   <0.001 
Obesity 48 (49.0) 36 (40.4) 70 (39.8) 0.31 
Diabetes 26 (25.7) 22 (25.9) 29 (17.3) 0.15 
         Current Smoker    6 (7.6) 4 (4.7)  4 (2.7) 0.25 
Cardiac Medications (% yes)     
        ASA 82 (70.7) 46 (58.2)
††
   131 (74.9)
††
 0.03 
        Statins  89 (76.7)
††
  44 (55.7)
††§§§
   140 (80.9)
§§§
 <0.001 
        Beta-blockers   94 (81.0)
†††∆  42 (53.2)
†††§§
  122 (70.1)
§§∆ <0.001 
       ACE-inhibitors 58 (50.0) 29 (36.7)
†
 90 (52.0)
†
 0.07 
       Calcium antagonists 26 (22.4)
†
   8 (10.1)
†
 24 (13.9) 0.05 
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       Anti-platelets    39 (30.5) 25 (25.3) 56 (30.4) 0.61 
      Anti-coagulants 23 (19.8)
†††
 10 (12.7) 10 (5.8)
†††
 0.001 
      Other anti-platelets 14 (10.9)   4 (4.0) 14 (7.6) 0.16 
      Other    75 (58.6)
††∆∆∆     42 (42.4)
††§§§
 144 (78.3)
§§§∆∆∆ <0.001 
 
†source is medical chart (hospital or cardiac rehabilitation program).  
§from pre-CR graded exercise stress test. 
†p<0.05, ††p<0.01; †††p<.001; §p<0.05, §§ p<0.01; §§§ p<.001; ∆p<0.05, ∆∆p<0.01, ∆∆∆p<0.001 
 
ASA= Acetylsalicyclic Acid; ACE=Angiotensin Converting Enzyme; MET=Metabolic Equivalent of 
Task; SD=Standard Deviation.  
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Table 5: Pre-CR Sociodemographic and Clinical Characteristics of Participants by CR 
Completion Status 
 
Characteristic  
Did not Complete 
CR (n=185; 47.0%) 
Completed CR 
(n=209; 53.0%) 
Total 
N=394 
P 
Sociodemographic      
Age (mean±SD years)†  63.7±10.9 65.4±9.7 64.5±10.4 0.18 
Sex (% male)† 96 (69.6) 151 (72.2) 286 (70.1) 0.34 
Marital status (% married) 75 (54.3)  130 (62.2) 236 (57.4) 0.09 
Education (% university or higher) 71 (51.4) 112 (53.6) 217 (52.8) 0.39 
Racial / Ethnic background, (% 
North American)  
40 (29.0) 68 (32.5) 126 (30.7) 0.28 
Work status (% retired)  43 (31.2) 80 (38.3) 145 (35.3) 0.11 
Clinical†     
Previous cardiac diagnosis (% 
yes) 
13 (9.4) 21 (10.0)   39 (9.5) 0.50 
Peak METs§ (mean±SD) 7.24±2.6 7.17±3.0 7.17± 2.9 0.08 
Referral Indication (% yes)     
Percutaneous Coronary 
Intervention 
  47 (34.8)  87 (42.9) 153 (39.8) 0.09 
Coronary Artery Disease   47 (34.8)  62 (30.8) 127 (33.2) 0.26 
Myocardial Infarction   31 (23.0)  53 (26.4) 100 (26.2) 0.28 
Coronary Artery Bypass 
Graft Surgery 
  36 (26.9)  61 (30.0) 109 (28.5) 0.31 
Arrhythmia   17 (12.7)  13 (6.5)   36 (9.5) 0.04 
Other    23 (16.7)  26 (12.4)   53 (12.9) 0.17 
Risk Factors (% yes)     
Dyslipidemia 110 (85.9) 149 (80.5) 293 (82.5) 0.14 
Hypertension 106 (79.7) 146 (73.4) 290 (76.9) 0.12 
Obesity 58 (43.9) 79 (42.0) 154 (42.4) 0.41 
Diabetes 34 (26.4) 37 (20.2) 77 (21.8) 0.13 
         Current Smoker   6 (5.8) 7 (4.3) 14 (4.5) 0.39 
Cardiac Medications (% yes)     
         ASA  83 (63.4) 144 (73.5) 259 (70.0) 0.04 
         Statins    98 (75.4) 144 (73.8) 273 (74.2) 0.43 
         Beta-blockers  86 (66.2) 141 (72.3) 258 (69.9) 0.14 
         ACE-inhibitors  62 (47.7) 92 (47.2) 177 (48.1) 0.51 
         Calcium antagonists  25 (19.2) 25 (12.8) 58 (15.8) 0.08 
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       Anti-platelets 42 (30.4) 61 (29.2) 120 (29.2) 0.45 
       Anti-coagulants  9 (6.9) 26 (13.3) 43 (11.7) 0.05 
       Other anti-platelets  9 (6.5) 17 (8.1) 32 (7.8) 0.37 
       Other  97 (70.3)   129 (61.7)    261 (63.5) 0.06 
 
*p<0.05 based on results of t-test or chi-square, as applicable. 
†source is medical chart (hospital or cardiac rehabilitation program).  
§from pre-CR graded exercise stress test. 
 
ASA= Acetylsalicyclic Acid; ACE=Angiotensin Converting Enzyme; MET=Metabolic Equivalent of 
Task; SD=standard deviation.
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Table 6: Quality Indicators and Findings 
 
QI# Domain Name Definition 
Indicator 
Finding 
(%) 
Available 
Benchmark 
CR-2a 
(P) 
Referral, 
access, and 
wait times 
CR wait time 
from hospital 
discharge 
% CR eligible 
inpatients who 
enrolled within 30 
days after hospital 
discharge* 
9.2% n/a 
CR-2b 
(P) 
CR wait time 
from referral to 
enrollment 
Median days between 
receipt of referral to 
patient enrollment 
Median # 
days 
35 
n/a 
CR-3 
(P) 
CR enrollment 
% patients who 
enrolled and 
underwent an intake 
assessment* 
93.7% 70%
57
 
CR-7 
(O) 
Secondary 
prevention: 
assessment, 
risk 
stratification 
and control 
Medication: 
ASA 
% CR patients who 
were prescribed ASA 
at program discharge 
70.0% 90%
29
 
CR-8 
(O) 
Medication: 
Other Anti-
platelet 
% CR patients 
prescribed anti-platelet 
agents other than ASA 
at program discharge 
33.5% n/a 
CR-9 
(O) 
Medication: 
Beta-Blockers 
% CR patients 
prescribed beta-
blockers at program 
discharge 
69.9% 90%
29
 
CR-10 
(O) 
Medication: 
Statins 
% CR patients 
prescribed statins at 
program discharge 
74.2% 90%
29
 
CR-12 
(O) 
Medications: 
ACE-i/ARB 
% CR patients 
prescribed ACE-i or 
ARBs at program 
discharge 
51.8% 90%
29
 
CR-13 
(P) 
Assessment of 
blood pressure 
% CR patients with 
assessment of blood 
pressure control 
98.1% 90%
6
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CR-14 
(P) 
Assessment of 
lipids  
% CR patients with 
assessment of lipid 
control 
53.0% n/a 
CR-15 
(P) 
Assessment of 
adiposity 
% CR patients with 
assessment of 
adiposity 
87.8% n/a 
CR-16 
(P) 
 
Assessment of 
blood glucose  
% diabetic patients 
with assessment of 
blood glucose control 
(HbA1C) 
42.1% 90%
6
 
CR-17 
(O) 
Behaviour 
change, 
program 
adherence & 
psychosocial 
education 
Increase in 
exercise capacity 
% CR patients with 
half MET increase in 
exercise capacity 
691% n/a 
CR-18 
(O) 
Adherence to 
CR program 
% prescribed exercise 
sessions completed 
64.1% n/a 
CR-
26 (P) 
Smoking 
cessation 
support 
% current or recent 
smokers who received 
smoking cessation 
support* 
66.7% n/a 
CR-30 
(P) 
Stress 
management 
% patients who 
received a stress 
management 
intervention* 
81.3% n/a 
CR-5 
(P) 
Self-
management 
education 
% CR patients who 
received self-
management education 
90.8% n/a 
CR-31 
(S) 
CR program 
model and 
structure 
Medical Director 
supervision 
% CR programs that 
have a physician 
medical director 
providing oversight 
100.0% n/a 
CR-32 
(S) 
Emergency 
response 
strategy 
% CR programs with a 
documented 
emergency response 
strategy and 
appropriately qualified 
staff 
100.0% n/a 
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CR-34 
(O) Discharge 
transition, 
linkage & 
communication 
Communication 
with PHCP 
% CR patients with a 
documented 
communication 
between program and 
PHCP 
94.2% n/a 
CR-37 
(O) 
CR Program 
completion 
% patients enrolled in 
CR who completed the 
program 
60.2% n/a 
n/a=not applicable or available.  
CR= Cardiac Rehabilitation 
ASA= Acetylsalicyclic Acid 
ACE-i= Angiotensin Converting Enzyme-inhibitor 
ARB= Angiotensin Receptor Blocker 
MET= Metabolic Equivalent of Task 
PHCP= Primary Health Care Provider 
HbA1C= Glycated Hemoglobin 
P=process indicator 
O=outcome indicator 
S=structure indicator 
*QI definition slightly modified.  
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Table 7: Quality Indicators by Cardiac Rehabilitation Site 
QI Name 
Indicator %  
p* 
Site 1 
(n=128, 31.1%) 
Site 2 
(n=99, 24.1%) 
Site 3 
(n=184, 44.8%) 
2a CR wait time from 
hospital discharge to 
enrollment 
 
10.2 
 
8.3 
 
0.0 
 
0.62 
2b CR wait time from 
referral to enrollment 
(median days) 
59.9
†††
 50.3
§§§
 29.3
†††§§§
 
 
<0.001 
3 CR enrollment   89.8 94.9    95.7  0.10 
5 Self-management 
education 80.0
§§†††
 98.3
†††
 95.9
§§
 
     
<0.001 
7 Medication: ASA 70.7 58.2
††
    74.9
††
    0.03 
8 Medication: Other 
Anti-platelet 26.4  38.8 37.0 
        
0.27 
9 Medication: Beta-
Blockers 81.0
†††∆  53.2
†††§§
  70.1
§§∆ 
     
<0.001 
10 Medication: Statins 
76.7
††
  55.7
††§§§
  80.9
§§§
 
     
<0.001 
12 Medications: ACE-
i/ARB 58.9       38.8  53.4 
0.09 
13 Assessment of blood 
pressure 98.7 100.0  96.0 0.22 
14 Assessment of lipid 
control 76.2
†††
       19.3
†††§§§
  91.9
§§§
 
    
<0.001 
15 Assessment of 
adiposity 71.9
†††§§§
    93.9
†††
  95.7
§§§
 
    
<0.001 
16 Assessment of blood 
glucose control 
 
70.7
†††§§§
 
 
        1.7
†††∆∆∆ 45.3
§§§∆∆∆ 
    
<0.001 
17 Increase in exercise 
capacity 65.7
†
 82.4
†§§
 59.7
§§
 0.01 
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*based on Analysis of Variance. 
†p<0.05, ††p<0.01; †††p<.001; §p<0.05, §§p<0.01; §§§p<.001; ∆p<0.05, ∆∆p<0.01, ∆∆∆p<0.001 
CR= Cardiac Rehabilitation 
ASA= Acetylsalicyclic Acid 
ACE-i= Angiotensin Converting Enzyme-inhibitor 
ARB= Angiotensin Receptor Blocker  
PHCP= Primary Health Care Provider 
 
 
 
  
18 Adherence to CR 
program 71.4§§§ 
 
77.0††† 
 
57.0†††§§§ 
     
<0.001 
34 Communication with 
PHCP 95.7 91.1 94.6 
     
0.58 
37 CR Program 
completion 71.4
§§§  73.8
†††
  46.3
†††§§§ 
 
<0.001 
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Table 8: Criterion Validity Exercise for CR QIs assessed in thesis  
 
QI# QI Name Original Variables used to 
compute the QI 
Variables that can be used to 
measure against 
2a CR Wait time 
from hospital 
discharge 
 
CRF1: 
p2 q4  discharge date 
p2 q5 Date CR Referral 
received 
;created syntax to subtract 
dates 
 
 
Discharge survey 
p23 q2 “Approx. how many wks 
passed between discharge and 
starting program?” 
 
 
3 CR Enrolment CRF1: 
Date of CR Intake 
Appointment- if one is present 
then, yes they enrolled 
 
Discharge Survey: 
Section M p21 “Did you attend a 
cardiovascular rehabilitation 
assessment (intake appointment)? 
–Yes/No 
 
17 Increase in 
exercise 
capacity 
CRF1: p4 q15b- Peak METs at 
intake 
CRF2: p3 q2c- Peak METs at 
discharge 
;created syntax to count 
patients who had increased 
capacity by ½ of intake MET 
by discharge 
 
Intake Survey 
Section B p4 q1-12- DASI score 
 
Discharge Survey 
Section A p2 q1-12- DASI score 
;compare DASI score from pre to 
post 
 
18 Adherence to 
CR program 
CRF2 
p2 q2-3 Number of sessions 
prescribed and number of 
sessions completed; calculated 
percentage 
Discharge survey 
p23 q4 “Approx. what % of CR 
sessions did you attend?” 
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Table 9: Values for each QI assessed for criterion validity from chart and corresponding self-
report data 
 
QI# QI name Chart (%) Self-report (%) 
2a 
CR Wait time from hospital 
discharge 
 
9.2 15.3 
3 CR Enrollment 83.7 47.4 
17 Increase in exercise capacity 69.1 28.7 
18 Adherence to CR program 64.1±32.1 66.9±39.8 
 
 
Table 10: Criterion validity results for 4 CR QIs 
 
QI# QI name Cohen’s kappa 
coefficient 
Pearson’s 
Correlation 
coefficient 
Interpretation
51
 
2a 
CR Wait time from 
hospital discharge 
 
0.21 n/a Fair 
3 CR Enrollment 0.22 n/a Fair 
17 
Increase in exercise 
capacity 0.17 n/a Slight 
18 Adherence to CR program n/a 0.17 None 
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Table 11: Canadian Cardiovascular Society Quality Indicator Exclusions not captured 
QI QI Definition QI Exclusion not captured 
QI-2a Wait time from hospital 
discharge 
 CR eligible patients with a documented 
medical reason and documented patient-
centered reason for non-referral  
 Patients being discharged to long-term care 
facility or inpatient rehabilitation. 
QI-2b Wait time from referral to 
enrollment 
 Patients experienced a new clinical event 
which is documented. 
 Patient delayed initial appointment date due 
to non-clinical factors, which are 
documented 
 
QI-3 % of patients enrolled in a 
program post-hospital 
discharge 
 Patient who at initial CR program 
assessment is determined to be not eligible 
for CR due to documented medical reason, 
such as co-morbid life-threatening 
condition, serious mental illness, or 
inability to ambulate.  
 Referred in-patients who are triaged or who 
attend another CR site.  
 CR Eligible patients with a documented 
medical reason for enrollment, such as 
recurrent event.  
 CR Eligible Patients with a documented 
patient-centered reason for non-referral. 
Patient being discharged to long-term care 
facility or inpatient rehabilitation. 
QI-7 % patients taking ASA at 
program discharge 
 Patients who are re-admitted to hospital 
before being discharged from CR program.  
 Patients with a documented reason (medical 
or patient-centered) for not taking ASA 
(e.g. post-surgical valve patient without 
CAD, allergy, severe bleeding). 
 
QI-8 % patients on anti-platelets 
other than ASA at program 
discharge 
 Patients who are re-admitted to hospital 
before being discharged from CR program.  
 Patients with a documented reason (medical 
or patient-centered) for not taking ASA 
(e.g. post-surgical valve patient without 
CAD, allergy, severe bleeding). 
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QI-9 % patients on beta blockers 
at program discharge 
 Patients who are re-admitted to hospital 
before being discharged from CR program.  
 Patients with a documented reason (medical 
or patient-centered) for not taking Beta-
blockers. 
 
QI-10 % of patients on statins at 
program discharge 
 Patients who are re-admitted to hospital 
before being discharged from CR program.  
 Patients with a documented reason (medical 
or patient-centered) for not taking Statins 
(e.g. patients who are statin-resistant). 
 
QI-12 % of patients taking 
ACEi/ARB at program 
discharge 
 Patients who are re-admitted to hospital 
before being discharged from CR program.  
 Patients with a documented reason (medical 
or patient-centered) for not taking ACEi/ 
ARB. 
QI-13 % patients who received 
individualized assessment 
of blood pressure control 
 Patients who are re-admitted to hospital 
before being discharged from CR program 
QI-14 % patients who received 
individualized assessment 
of lipid control 
 Patients who are re-admitted to hospital 
before being discharged from CR program. 
QI-15 % patients who received 
individualized assessment 
of adiposity 
 Patients who are re-admitted to hospital 
before being discharged from CR program. 
QI-16 % patients who received 
individualized assessment 
of blood glucose control: 
 Patients who are re-admitted to hospital 
before being discharged from CR program. 
QI-30 % patients who were 
referred to a stress 
management intervention 
 Patients who have a documented patient-
centered reason for not being offered stress 
management (i.e., perceive no difficulty 
with stress) 
QI-34 % patients with a 
documented 
communication between 
the CR program and 
primary health care 
practitioner 
 Patients who are re-admitted to hospital 
before being discharged from CR program.  
 Patient has no primary health care provider. 
 
CR= Cardiac Rehabilitation; ASA= Acetylsalicyclic Acid; CAD= Coronary Artery Disease 
ACEi= Angiotensin Converting Enzyme Inhibitor; ARB= Angiotensin II Receptor Blockers    
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13.0 APPENDICES 
Appendix A: Example of site-specific Informed Consent Form  
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
  
STUDY NAME:  Cardiovascular Rehabilitation—Chronic Disease Management Program 
Evaluation and Cost-Effectiveness Analysis 
STUDY SPONSOR: N/A 
INVESTIGATORS:   
Sherry L. Grace, PhD (Principal Investigator) York University and University Health 
Network 
Caroline Chessex, MD (Co-Principal 
Investigator) 
University Health Network  
 
Doug S. Lee, MD (Co-Investigator) Institute for Clinical Evaluative Sciences 
and University Health Network 
Harindra Wijeysundera, MD (Co-Investigator) Sunnybrook Health Sciences Centre and 
University of Toronto 
Mansoor Husain, MD (Co-Investigator) University Health Network 
Nickan Motamedi (BSc Student) York University 
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You are being asked to take part in a research study. Please read this explanation about the study and its 
risks and benefits before you decide if you would like to take part. You should take as much time as you 
need to make your decision. You should ask the study doctor or study staff to explain anything that you 
do not understand and make sure that all of your questions have been answered before signing this 
consent form. Before you make your decision, feel free to talk about this study with anyone you wish. 
Participation in this study is voluntary. 
 
Background and Purpose 
 
You have already agreed to participate in the PMCC Cardiovascular Rehabilitation and Prevention 
Program. In this research study, we would like to include your information collected in this program for 
research purposes. We would like to use this information to learn how we can better meet the needs of our 
patients and to improve the services we provide. We would like to better understand how your quality of 
life, heart risk factors, knowledge and health behaviors change following participation in CR. We are also 
interested in studying the cost-effectiveness of the services we provide to you. 
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Study Design and Procedures 
 
As part of our program, you will be asked to complete 4 surveys online: one at the beginning of the 
cardiovascular rehab program, one 6 months, 12 months, 24 months. The surveys include questions about 
your exercise and nutrition habits, medication adherence, quality of life, and mood. These questions help 
us understand how you are managing your health condition. Your completion of all surveys is voluntary. 
You can provide your email address at the end of this form to receive an email link to the survey. 
Alternatively, you can complete the survey on paper and mail it back to us in a pre-paid envelope.  
If you consent to participate in this study, your survey responses would be used for research purposes. If 
your survey responses in the mood section suggest that you may have elevated depressive symptoms, we 
will send a letter to your family doctor to let him/her know. We would also like to extract clinical 
information from your charts (e.g., disease history, other health problems, risk factors, exercise stress test 
results, cholesterol levels, your medications). Finally, we would also like your permission to link your 
information gathered from this program with a provincial database to determine your health care use and 
health outcomes over time. This would not require any paperwork on your behalf.   
 
Potential Benefits and Risks  
 
The risks and benefits involved in the program have already been explained to you.   
 
You may or may not receive any direct benefit from being in this study. Information learned 
from this study may help other people with your condition in the future.  
 
There are no additional risks to you if you take part in this study. Being in this study may make you feel 
uncomfortable. You may refuse to answer questions if there is any discomfort. 
 
As a general reminder, email may not always be a secure method of communication. For this 
study, email is being used for general communication purposes only, and will not be used to 
collect/provide personal health information.  If you take part in this study, please be reminded 
that personal information will be collected in a de-identified manner through the online survey. 
 
Confidentiality  
If you agree to join this study, the study doctor and his/her study team will look at your personal health 
information and collect only the information they need for the study. Personal health information is any 
information that could be used to identify you and includes your: 
 name,  
 email address 
 address,  
 OHIP number, new or existing medical records, that includes types, dates and results of medical 
tests or procedures.   
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The information that is collected for the study will be kept in a locked and secure area by the study doctor 
for 10 years. Only the study team or the people or groups listed below will be allowed to look at your 
records.  Your participation in this study also may be recorded in your medical record at this hospital.   
 
Representatives of the University Health Network Research Ethics Board may look at the study records 
and at your personal health information to check that the information collected for the study is correct and 
to make sure the study followed proper laws and guidelines. 
 
We are collaborating with some other programs in the province, to study how self-management 
education varies in different programs. Therefore, parts of the information you provide in your 
survey may be securely and anonymously shared with the research investigators from this larger 
study.  
 
Please note that any information that you provide for this study in the online survey, even though 
de-identified, when transferred to the U.S, is subject to U.S. laws, and in particular, to the U.S. 
Patriot Act. The US Patriot Act allows authorities access to the records of study participants in 
the event of auditing by authorities. 
 
All information collected during this study, including your personal health information, will be kept 
confidential and will not be shared with anyone outside the study unless required by law.  You will not be 
named in any reports, publications, or presentations that may come from this study.   
 
If you decide to leave the study, the information about you that was collected before you left the study 
will still be used.  No new information will be collected without your permission.  
Questions About the Study 
 
Feel free to speak to one of our staff members if you have any questions or concerns. You may contact 
the study coordinator at cdmstudy@yorku.ca or (416) 736-2100 ext 20575. 
Should you have any questions about your rights as a research participant, please contact the University 
Health Network Research Ethics Board at (416) 946-4438.  
 
CONSENT 
 This study has been explained to me and any questions I had have been answered. I know that I may 
leave the study at any time. I agree to take part in this study.  
Date: ____________________   
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Appendix B: Intake Case Report Form 
 
1. Site:  
 UHN 
 YCH 
 Southlake 
 
2. Patient Ineligible for Study:  
 
 Yes (if yes, specify below) 
 No 
 
 Lack of proficiency in language of ICF and surveys 
 Other, please specify: 
_____________________________________________________ 
 
3. Patient Declined to Participate:  
 
 No   Yes -Reason, if willing: 
_____________________________________________ 
Stop here if patient is ineligible or declined. 
 
PAGE 2: Study ID#: __________________ 
 
1. Age  
 
2. Sex  Male  Female 
 
3. Inpt Admission Date- 
  
4. Inpt Discharge Date- 
 
5. Expected Date of CR- 
 
6. Referral Indication (check all that apply) 
 Cardiac 
 yrs 
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 PCI  
 CABG Surgery and/or Valve surgery 
 TAVI/PAVI 
 Stable Angina / CAD 
 MI  
 HF 
 Congenital 
 Arrhythmia / ICD / Pacemaker 
 Heart Transplant 
 VAD 
 Stroke / TIA 
 Diabetes 
 Renal  
 PVD 
 Arthritis Clinic 
 Other, please specify _____________________ 
 
 
 Date assessed: _________________ 
 
3. CCS Angina Class: 
            0     1     2     3     4              
           IV-a   IV-b   IV-c  IV-d   
                    
4. NYHA Functional Class: 
       1     2     3     4 
 
5. LV Function:  
 Nuclear     Echo      Angiogram 
 LVEF %: _____________ 
 Narrative: __________________________ _____________________________________ 
  
   Normal    Mild   Moderate     Severe 
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7. Risk Factors 
 
Yes No Factor Details 
  Diabetes 
Type  Type I  Type II 
HbA1c%  
Date assessed    
dd mmm yyyy 
  Obesity (BMI>30) 
BMI (kg/m2)  
Waist circ (cm)  
Date assessed    
dd mmm yyyy 
  Hypertension 
Blood Pressure 
(BP) 
  
systolic diastolic 
Date assessed    
dd mmm yyyy 
  Dyslipidemia 
Total Cholesterol  
HDL  
LDL  
Triglycerides  
Date assessed    
dd mmm yyyy 
 
8. Previous cardiac diagnoses (check all that apply)? 
 
6. Complications during stay: 
 Arrhythmia 
 Recurrent Angina / 
ischemia 
 Cardiogenic shock 
 Cerebrovascular 
Accident 
 Readmit (ICU /   
CCU) 
 Infection 
 Cardiac Arrest  
 Pericarditis 
 Pneumonia 
 Acute Renal Fail 
 DVThrombosis 
 MI 
 Cardioversion  
 Cardiac                                                                       
Tamponade 
 Other: specify: 
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9. Comorbid Conditions (check all that apply)
 CAD 
 HF 
 Arrhythmia/Device 
 Congenital HD 
 ACS/MI 
 VAD 
 Infection  
 Valve condition 
 TAVI/PAVI 
 Cardiomyopathy  
 Other: ___________ 
 None 
 Cancer 
 Hyperthyroid 
 Liver Disease 
 PAD/PVD 
 Depression 
 Renal Disease 
 MSK / Joint Replacement, specify: _____ 
 Other: _____________________ 
54 
 
Resting heart rate: ____________ 
10. hs-CRP: ______________________ 
11. BNP: ___________________ 
12. CBC: _______________________ 
 
13. Intake Exercise Stress Test (circle one for each) 
a. Completed:  No  Yes, date:  
b. Peak METs: ______________ 
c. Peak VO2: _______________ 
d. GXT     or     CPA     
e. Symptom-limited?     Yes    No 
f. Mode?    Treadmill  Bike 
g. Protocol? Bruce Modified Bruce  Other, specify: 
h. Other comments: 
___________________________________________________________________________
_____________________________________________________________________ 
 
14. Current Medications (check all that apply): 
 ACE Inhibitors 
 Anti-coagulants 
 ASA 
 Ca2+ antagonists 
 Statin 
 LL – fibrate 
 LL – nicotinic acid 
 LL – resin drugs 
 Diuretics 
 Clopidogrel or ticlopidine 
 Other anti-platelet 
 Nicotine Replacement 
 Anti-arrhythmic 
  Anti-platelets 
 Beta-blockers 
 Digoxin 
 Nitrates (not PRN) 
 ARBs 
 Anti-depressant 
 Coumadin 
 Heparin 
 HRT 
 Insulin 
 Oral hypoglycemic 
 Anti-inflammatory 
 Other _______________ 
 Not reported in chart 
   
dd mmm yyyy 
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Appendix C: Discharge Case Report Form 
 
1. Program elements utilized by patient (check all that apply):  
 Education session(s) 
 On-site exercise 
 Home-based exercise program 
 Dietitian consult 
 Smoking cessation referral or consult 
 Pharmacy consult 
 Diabetes education referral or consult 
 Stress management, or psychosocial referral / consult 
 Other, please specify:________________________________________________________________ 
 
2. Number of Sessions prescribed: _____________ 
 
3. Number of sessions completed: _____________  or   information not available in chart 
 
4. Any untoward events detected during exercise sessions: 
 Yes, please specify: ______________________________________________ 
 No 
 Not documented in chart  
 
5. Did the patient complete the program? Yes  No 
If yes: Date of graduation:  
If no, reason indicated in chart?  
 No 
 Yes, please specify whether: 
 clinical  not clinical 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
dd mmm yyyy 
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6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Resting heart rate: ___________ 
Date assessed  
 
 
2. Discharge Exercise Stress Test 
a. Completed:  No  Yes, date:  
b. Peak METs: ______________ 
c. Peak VO2: _______________ 
 
d. GXT     or     CPA    (circle one for each) 
 
e. symptom-limited?     Yes    No 
 
f. mode?    Treadmill  Bike 
 
Yes No Risk Factors Details 
  Diabetes 
Type  Type I  Type II 
HbA1c%  
Date assessed    
dd mmm yyyy 
  Obesity (BMI>30) 
BMI (kg/m2)  
Waist circ (cm)  
Date assessed    
dd mmm yyyy 
  Hypertension 
Blood Pressure (BP)   
systolic diastolic 
Date assessed    
dd mmm yyyy 
  Dyslipidemia 
Total Cholesterol  
HDL  
LDL  
Triglycerides  
Date assessed    
dd mmm yyyy 
   
dd mmm yyyy 
   
dd mmm yyyy 
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g. Protocol? Bruce modified Bruce  Other, specify: 
 
h. Other comments: 
_______________________________________________________________________________
_________________________________________________________________ 
 
3. Chart indication discharge report mailed to other healthcare provider(s) involved in patient care? 
 Yes 
 No 
 
4. Medications at Discharge (check all that apply): 
 ACE Inhibitors 
 Anti-coagulants 
 ASA 
 Ca2+ antagonists 
 Statin 
 LL – fibrate 
 LL – nicotinic acid 
 LL – resin drugs 
 Diuretics 
 Clopidogrel or 
ticlopidine 
 Other anti-platelet 
 Nicotine Replacement 
 Anti-arrhythmic 
 Anti-platelets 
 Beta-blockers 
 Digoxin 
 Nitrates (not PRN) 
 ARBs 
 Anti-depressant 
 Coumadin 
 Heparin 
 HRT 
 Insulin 
 Oral hypoglycemic 
 Anti-inflammatory 
 Other: 
__________________
________ 
 Not reported in chart
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Appendix D: Intake Survey sections utilized 
 
SECTION A: YOUR SOCIO-DEMOGRAPHIC CHARACTERISTICS 
1. What do you consider to be your racial/ethnic background? Please check   one (1) of the 
following boxes: 
 North American (e.g., Canadian, American) 
 French (not French-Canadian) 
 British Isles (e.g., British, Scottish, Irish) 
 Western European (e.g., Austrian, Belgian, German, Swiss) 
 Northern European (e.g., Danish, Finnish) 
 Eastern European (e.g., Hungarian, Ukrainian, Polish, Czech) 
 Southern European (e.g., Greek, Italian, Spanish) 
 Jewish 
 African 
 Arab 
 West Asian (e.g., Afghan, Armenian, Iranian) 
 South Asian (e.g., East Indian, Punjabi, Pakistani) 
 East or South East Asian (e.g., Chinese, Filipino, Japanese, Vietnamese, Thai, Laotian) 
 Oceania (e.g., Australian, New Zealander, Pacific Islanders) 
 Caribbean 
 Latin, Central, or South American 
 Aboriginal (e.g., Métis, Inuit) 
 Other (specify: _______________________________) 
 
 Multiple cultural backgrounds (specify: _____________________________) 
 
2. Please rate how comfortable you are speaking, reading and writing in English:  
 Not comfortable 
 I can get by, but am more comfortable using a language other than English 
 Fairly comfortable 
 Very comfortable communicating in English 
 
3. What is your marital status: 
 Married/common-law 
 Separated/divorced 
 Single 
 Widow 
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4. What is the highest level of education you have completed? 
 less than grade 9  
 less than high school  
 completed high school  
 some college or university courses    
 completed college or university degree 
 Graduate School/Professional Program 
 
5. Which option best matches your current work status? 
 full-time work 
 part-time work 
 full-time caregiver or homemaker (inside your home) 
 unemployed 
 receiving disability 
 retired 
 other: ______________________ 
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Appendix E: Full Quality Indicators assessed  
PROCESS INDICATOR NO: CR-2a 
CARDIAC REHABILITATION WAIT TIME FROM HOSPITAL DISCHARGE  
Description 
Percentage of eligible in-patients who were referred to CR and who enroll in CR within 30 days 
after hospital discharge. 
Numerator The total number of eligible in-patients enrolled in the CR Program within 30 calendar days post-
discharge for any of the qualifying conditions or interventions: 
 Acute coronary syndrome; 
o Acute Myocardial Infarction (STEMI, non-STEMI); 
o Unstable angina;  
 Percutaneous coronary intervention;  
 Coronary artery bypass surgery;  
 
Enrollment is defined as patient attendance at a first CR program visit.  
Denominator The total number of eligible in-patients (see numerator) enrolled in the CR Program. 
 
Exclusions: 
 CR Eligible Patients with a documented medical reason for non-referral, such as 
comorbid life-threatening condition, serious mental illness, or inability to ambulate. 
 CR Eligible Patients with a documented patient-centered reason for non-referral. 
 Patient being discharged to long-term care facility or inpatient rehabilitation. 
Period of 
Assessment 
At least annually. 
Sources of Data Electronic medical records, retrospective chart review, prospective flow sheets, Provincial and 
territorial hospital discharge abstract databases, CIHI hospital database, and/or cardiac 
registries. 
Rationale 
At present, there is limited evidence testing whether timely referral and entry into CR reduces morbidity and mortality 
compared with delayed referral and/or entry into CR. There is some evidence that facilitated referral to CR and rapid 
program enrollment may increase rates of program attendance and program completion (Parker et al., 2009; Russell 
et al., 2011), even among smokers, and is safe in low-risk patients (Robinson et al., 2011). Moreover, there is some 
evidence that early initiation of exercise has beneficial effects on exercise self-efficacy (Dolansky et al., 2011), 
maximum oxygen consumption achieved in CR (Valkeinen et al., 2010) and left ventricular function (Haykowsky et 
al., 2011).  
 
References: 
 Parker, K., Stone, J. A., Arena, R., Lundberg, D., Aggarwal, S., Goodhart, D., & Traboulsi, M. (2011). An Early 
Cardiac Access Clinic Significantly Improves Cardiac Rehabilitation Participation and Completion Rates in Low-
Risk ST-Elevation Myocardial Infarction Patients. Canadian Journal of Cardiology, 27(5), 619-627. 
 Russell, Kelly L., Tanya M. Holloway, Margaret Brum, Veola Caruso, Caroline Chessex, and Sherry L. Grace. 
"Cardiac rehabilitation wait times: effect on enrollment." Journal of Cardiopulmonary Rehabilitation and 
Prevention 31, no. 6 (2011): 373.  
 Robinson HJ, Samani NJ, Singh SJ. Can low risk cardiac patients be 'fast tracked' to Phase IV community 
exercise schemes for cardiac rehabilitation? A randomised controlled trial. International Journal of Cardiology 
2011 Jan 21;146(2):159-63. 
 Dolansky MA, Zullo MD, Boxer RS, Moore SM. Initial efficacy of a cardiac rehabilitation transition program: 
Cardiac TRUST. Journal of Gerontological Nursing 2011 Dec;37(12):36-44. 
 Valkeinen H, Aaltonen S, Kujala UM. Effects of exercise training on oxygen uptake in coronary heart disease: A 
systematic review and meta-analysis. Scandinavian Journal of Medicine and Science in Sports 2010 
Aug;(4):August. 
Clinical Recommendation(s) 
All patients referred to CR should undergo entry assessment in a timely fashion.  
 
Modified from Reference: 
 Canadian Cardiovascular Society Access to Care Working Group on Cardiac Rehabilitation, Dafoe et al., 2006).  
(Strong Recommendation, Moderate to Low Quality Evidence) 
Method of Reporting 
The reported statistic will be a percentage. 
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Challenges to Implementation 
 May be difficult to determine date of discharge where inpatients are referred post-discharge. 
 
 
PROCESS INDICATOR NO: CR-2b 
CARDIAC REHABILITATION WAIT TIME FROM REFERRAL TO ENROLLMENT 
Description 
The median number of days between referral at the Cardiac Rehabilitation (CR) program to 
patient enrollment. 
Numerator The number of calendar days from receipt of referral at the CR program to patient 
enrollment 
Denominator All patients enrolled in the CR program in the reference period. 
Exclusions: 
 Patient experienced a new clinical event, which is documented. 
 Patient delayed initial appointment date due to non-clinical factors, which are 
documented 
(e.g. personal travel). 
 
Method of 
Calculation 
Median number of days, calculated for the population of reference as 
described in the denominator section. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
At present, there is limited evidence testing whether timely referral and entry into CR reduces morbidity and 
mortality compared with delayed referral and/or entry into CR. There is some evidence that facilitated referral to 
CR and rapid program enrollment may increase rates of program attendance and program completion (Parker 
et al., 2009; Russell et al., 2011), even among smokers, and is safe in low-risk patients (Robinson et al., 2011). 
Moreover, there is some evidence that early initiation of exercise has beneficial effects on exercise self-efficacy 
(Dolansky et al., 2011), maximum oxygen uptake (Valkeinen et al., 2010) and the left ventricle (Haykowsky et 
al., 2011). 
 
References: 
 Parker, K., Stone, J. A., Arena, R., Lundberg, D., Aggarwal, S., Goodhart, D., & Traboulsi, M. (2011). 
An Early Cardiac Access Clinic Significantly Improves Cardiac Rehabilitation Participation and 
Completion Rates in Low- Risk ST-Elevation Myocardial Infarction Patients. Canadian Journal of 
Cardiology, 27(5), 619-627. 
      Russell, K. L., Holloway, T. M., Brum, M., Caruso, V., Chessex, C., & Grace, S. L. (2011). 
Cardiac rehabilitation wait times: effect on enrollment. Journal of Cardiopulmonary  
Rehabilitation and Prevention, 31(6), 373 
 Robinson, H. J., Samani, N. J., & Singh, S. J. (2011). Can low risk cardiac patients be ‘fast tracked’to 
Phase IV community exercise schemes for cardiac rehabilitation? A randomised controlled trial. 
International journal of cardiology,146(2),  159-163. 
      Dolansky, M. A., Zullo, M., Boxer, R., & Moore, S. M. (2011). Initial Efficacy of a Cardiac Rehabilitation 
Transition Program: Cardiac TRUST. Journal of Gerontological Nursing, 37(12), 36. 
      Valkeinen, H., Aaltonen, S., & Kujala, U. M. (2010). Effects of exercise training on oxygen 
uptake in coronary heart disease: a systematic review and meta-analysis.  Scandinavian 
journal of medicine & science in sports, 20(4), 545-555. 
 Haykowsky, M., Scott, J., Esch, B., Schopflocher, D., Myers, J., Paterson, I., ... & Clark, A. M. (2011). A 
Meta- analysis of the effects of Exercise Training on Left Ventricular Remodeling Following Myocardial 
Infarction: Start early and go longer for greatest exercise benefits on remodeling. Trials, 12(1), 92. 
Clinical Recommendation(s) 
All patients referred to CR should undergo entry assessment in a timely fashion so their CR program can be 
initiated. 
 
Modified from Reference: 
 Dafoe, W., Arthur, H., Stokes, H., Morrin, L., & Beaton, L. (2006). Canadian Cardiovascular  
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Society Access to Care Working Group on Cardiac Rehabilitation. Universal access: but 
when? Treating the right patient at the right time: access to cardiac rehabilitation. Can J 
Cardiol, 22(11), 905-911 (Strong Recommendation,  Low Quality Evidence) 
Method of Reporting 
The reported statistic will be a median. 
Challenges to Implementation/Interpretation 
 Information required to identify exclusions may be variably ascertained and documented. 
 
 
 
PROCESS INDICATOR NO: CR-3 
CARDIAC REHABILITATION ENROLLMENT 
Description Percentage of CR-eligible patients enrolled in a program post hospital discharge. 
Numerator The total number of eligible patients enrolled in the CR Program.  
 
Enrollment is defined as patient attendance at a first CR program visit.  
Denominator The total number of eligible patients referred to the CR Program post hospital discharge. 
 
A referral is deemed being made if both of the following criteria are satisfied: 
1. There is an official written or electronic communication on behalf of the health care provider 
for referral to CR.  
2. The referral information has been received by the CR program. 
 
Exclusions: 
 Patient who at initial CR program assessment is determined to be not eligible for CR due to 
documented medical reason, such as comorbid life-threatening condition, serious mental 
illness, or inability to ambulate.  
 Referred inpatients who are triaged or who attend another CR site. 
 CR Eligible Patients with a documented medical reason for enrollment, such as recurrent 
event. 
 CR Eligible Patients with a documented patient-centered reason for non-referral. 
 Patient being discharged to long-term care facility or inpatient rehabilitation. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
CR improves mortality and morbidity. Evidence supports high concordance between referral and patient enrollment 
rates. Enrolment rates of 80% of those referred have been reported in institutions where systematic CR referral is 
deployed. 
 
Modified from Reference: 
 Grace, S. L., Chessex, C., Arthur, H., Chan, S., Cyr, C., Dafoe, W., et al. (2011). Systematizing inpatient referral 
to cardiac rehabilitation 2010 CANADIAN ASSOCIATION OF CARDIAC REHABILITATION AND CANADIAN 
CARDIOVASCULAR SOCIETY JOINT POSITION PAPER. Journal of Cardiopulmonary Rehabilitation and 
Prevention, 31(3), E1-E8. 
Clinical Recommendation(s) 
All eligible CR in-patients should enroll in a CR program following hospital discharge. 
(Strong Recommendation, Moderate Quality Evidence) 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
  Lack of systematic CR referral information capture by programs. Systematic (electronic preferred) prospective 
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information capture will help alleviate challenges. 
 
PROCESS INDICATOR NO: CR-5 
PATIENT SELF-MANAGEMENT EDUCATION 
Description 
The percentage of patients in the Cardiac Rehabilitation (CR) Program who received patient 
self- management education either individually or within a group prior to program discharge 
Numerator A subset of the denominator representing a number of patients for whom there is 
documentation  of receiving patient self-management  education as defined by the CACR 
Guidelines (see below) before program discharge. 
 
This education is defined as not only information provision concerning the core areas of 
CR, but also theoretically-informed behaviour change techniques (see Clinical 
Recommendations for the definition of the self-management  education). 
  
Denominator The number of patients discharged from the CR program in the reference period. 
Method of 
Calculation 
Numerator / Denominator * 100 
. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
While patient education may not reduce all-cause mortality or cardiac morbidity, educational interventions can 
significantly improve health-related quality of life.  We would argue that a key objective of patient education is to 
increase knowledge and understanding,  which is necessary for heart-healthy behaviour change, which in turn 
reduces cardiac risk 
 
Reference 
 Brown, J. P., Clark, A. M., Dalal, H., Welch, K., & Taylor, R. S. (2012). Effect of patient education in the 
management of coronary heart disease: a systematic review and meta-analysis of randomised controlled 
trials. European Journal of Preventive Cardiology 
Clinical Recommendation(s) 
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (v2012): 
 Multimodal interventions integrating education on healthy lifestyle medical resources are recommended. 
 
Based on the CACR 3
rd
 Edition Guidelines, patient self-management education: 
 Includes an informational component which:  
1. Discusses specific health goals;  
2. Is personalized;  
3. Explains the risks of not changing, the benefits of changing, and seeks to influence outcome beliefs 
regarding the outcome efficacy of interventions or behavioural changes;  
4. Often emphasizes proximal risks and benefits over distal ones;  
5. Seeks to heighten self-efficacy concerning possible effective self-regulation of specific behaviours; and,  
6. May seek to elicit positive emotions, to increase optimism about the possibility of change, and to 
heighten the salience of personal experience or other evidence supporting self-efficacy 
 Is led by professional staff, and not by lay persons, with regular contact between staff and patients. 
 Can be delivered as stand-alone sessions (which is preferred) or incorporated into other activities. Where the 
delivery is incorporated into other activities the goals of the education must be clearly defined and delivered.  
 Education can be delivered in individual or group settings. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Detailed information on the content of the self-management  education is required for this indicator to be 
comparable across CR programs. 
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OUTCOME INDICATOR NO: CR-7 
SECONDARY PREVENTION MEDICATIONS: ACETYLSALICYLIC ACID (ASA) 
Description Percentage of patients who were taking ASA at time of CR program discharge. 
Numerator The total number of patients enrolled in a CR program who were taking ASA at time of discharge 
from CR program.  
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team.   
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patients with a documented reason (medical or patient-centered) for not taking ASA (e.g. 
post-surgical valve patient without CAD, allergy, severe bleeding). 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Antiplatelet agents are a cornerstone therapy for patients with documented atherosclerotic vascular disease. There is 
clear evidence showing its benefit in preventing adverse cardiovascular events in patients with vascular diseases.  
 
CR program staff should discuss medication use with patients at program initiation and completion at a minimum, and 
this should be documented in the patient’s chart. Drug regimen changes should be done in the appropriate manner 
during the CR program in order to reach optimal CV medication use and risk reduction.  
 
Communication should be made with the primary care provider as well as the pharmacist.  
Clinical Recommendation(s) 
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic 
Vascular Disease: 2011 Update: 
 Aspirin 75–162 mg daily is recommended in all patients with coronary artery disease unless contraindicated. 
(Class I; Level of Evidence: A). 
CCS 2011 Antiplatelet Guidelines. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Contraindication or significant side effects to ASA will need to be specifically documented. 
 Because ASA is provided over-the-counter, use may be more difficult to ascertain. 
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OUTCOME INDICATOR NO: CR-8 
SECONDARY PREVENTION MEDICATIONS: ANTI-PLATELET AGENTS OTHER THAN ASA 
Description 
Percentage of patients on anti-platelet agents other than ASA (i.e. 
Clopidogrel/Prasugrel/Ticagrelor) at time of CR program discharge. 
Numerator The total number of patients enrolled in CR program who have an indication for anti-platelets as 
per CCS guidelines taking anti-platelet agents other than ASA (i.e. 
Clopidogrel/Prasugrel/Ticagrelor) at time of CR program discharge. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team.   
Denominator The total number of patients discharged from the CR program who have an indication for other 
anti-platelet agents. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patients with a documented reason (medical or patient-centered) for not taking other anti-
platelet agents. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Antiplatelet agents are a cornerstone therapy for patients with documented atherosclerotic vascular disease. There is 
clear evidence showing its benefit in preventing adverse cardiovascular events in patients with vascular diseases.  
 
CR program staff should discuss medication use with patients at program initiation and completion at a minimum, and 
this should be documented in the patient’s chart. Drug regimen changes should be done in the appropriate manner 
during the CR program in order to reach optimal CV medication use and risk reduction.  
 
Some patients will enter CR on another antiplatelet agent, which will appropriately be discontinued during the time of 
CR.  
 
Communication should be made with the primary care provider as well as the pharmacist. 
Clinical Recommendation(s) 
CCS 2011 Antiplatelet Guidelines. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Contraindication or significant side effects to Clopidogrel/Prasugrel/Ticagrelor will need to be specifically 
documented. 
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OUTCOME INDICATOR NO: CR-9 
SECONDARY PREVENTION MEDICATIONS: BETA BLOCKERS 
Description Percentage of patients on a Beta-blocker at CR discharge. 
Numerator The total number of patients in the CR program who were indicated for and taking Beta-blockers 
at time of CR program discharge. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team.   
Denominator The total number of patients indicated for beta-blockers discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patients with a documented reason (medical or patient-centered) for not taking Beta-
blockers. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
The appropriate use of preventive medications can reduce recurrent cardiovascular events and improve patient 
outcomes. CR program staff should discuss medication use with patients at program initiation and completion at a 
minimum, and this should be documented in the patient’s chart. Drug regimen changes should be done in the 
appropriate manner during the CR program in order to reach optimal CV medication use and risk reduction. 
Communication should be made with the primary care provider as well as the pharmacist. 
Clinical Recommendation(s) 
CACR 3
rd
 Edition Guidelines: 
 All patients with clinically-significant coronary artery disease or heart failure who have an indication for beta-
blockade, without clear contraindications or a history of beta-blocker intolerance, should be considered for 
chronic beta-blocker therapy. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Contraindication or significant side effects to Beta-blockers will need to be specifically documented. 
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OUTCOME INDICATOR NO: CR-10 
SECONDARY PREVENTION MEDICATIONS: STATINS 
Description Percentage of CR patients on statins at program discharge. 
Numerator The total number of patients enrolled in CR program who were taking Statins at program 
discharge. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team.   
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patients with a documented reason (medical or patient-centered) for not taking Statins (e.g. 
patients who are statin-resistant). 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
A lipid profile should be established in all patients, with lipid-lowering therapy initiated. An adequate does of statin 
should be used to achieve lipid targets. Statin therapy has a beneficial effect on atherosclerotic CVD outcomes.  
 
Statin-intolerant patients should be considered for other hypo-lipidemic agents. 
Clinical Recommendation(s) 
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic 
Vascular Disease: 2011 Update: 
 In addition to therapeutic lifestyle changes, statin therapy should be prescribed in the absence of 
contraindications or documented adverse effects (Level of Evidence: A) 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Contraindication or significant side effects to Statins will need to be specifically documented. 
 
 
 
 
 
 
 
 
 
 
68 
 
OUTCOME INDICATOR NO: CR-12 
SECONDARY PREVENTION MEDICATIONS: ACE/ARB 
Description 
Percentage of patients at CR discharge on angiotensin-converting enzyme (ACE) inhibitors / 
Angiotensin Receptor Blockers (ARBs) 
Numerator The total number of patients enrolled in CR program indicated for ACE / ARB who were taking 
ACE / ARB at program discharge. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team.   
Denominator The total number of patients indicated for ACE / ARB discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patients with a documented reason (medical or patient-centered) for not taking ACE / ARB. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
The appropriate use of preventive medications can reduce recurrent cardiovascular events and improve patient 
outcomes. 
Clinical Recommendation(s) 
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic 
Vascular Disease: 2011 Update 
 
 ACE inhibitors  
a. ACE inhibitors should be started and continued indefinitely in all patients with left ventricular ejection fraction 
≤40% and in those with hypertension, diabetes, or chronic kidney disease, unless contraindicated. (Class I; 
Level of Evidence: A) 
b. It is reasonable to use ACE inhibitors in all other patients.126 (Class IIa; Level of Evidence: B) 
 
 ARBs  
a. The use of ARBs is recommended in patients who have heart failure or who have had a myocardial 
infarction with left ventricular ejection fraction ≤40% and who are ACE-inhibitor intolerant. (Class I; Level of 
Evidence: A) 
b. It is reasonable to use ARBs in other patients who are ACE-inhibitor intolerant. (Class IIa; Level of Evidence: 
B) 
 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Contraindication or significant side effects to ACE / ARB will need to be specifically documented. 
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PROCESS INDICATOR NO: CR-13 
ASSESSMENT OF BLOOD PRESSURE CONTROL 
Description 
Percentage of patients in CR program who received individualized assessment of blood 
pressure (BP) control. 
Numerator The total number of enrolled CR patients for whom an assessment of blood pressure control 
was made. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Assessment of cardiovascular (CV) risk factors including blood pressure should be made at program entry and exit in 
order to determine cardiovascular risk, identify patients who are not at target and monitor antihypertensive treatment. 
Canadian Hypertension Education Program recommendations regarding patient preparation, posture and position, 
equipment, and technique should be followed to ensure accurate assessment.  
 
Subsequently, risk factor management should be undertaken in the appropriate manner during the CR program in 
order to reach optimal CV risk factor goal by program completion. Blood pressure control is defined as systolic and 
diastolic mmHg values which are ≤ the guideline-recommended threshold. Programs should aim to achieve blood 
pressure control in at least 90% of patients (benchmark). 
Clinical Recommendation(s) 
Canadian Hypertension Education Program Recommendations 2012 
a. Health care professionals who have been specifically trained to measure BP accurately should assess BP in 
all adult patients at all appropriate visits to determine cardiovascular risk and monitor antihypertensive 
treatment (Grade D). 
b. Use of standardized measurement techniques is recommended when assessing BP (Grade D). 
 
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic 
Vascular Disease: 2011 Update 
a. All patients should be counseled regarding the need for lifestyle modification to achieve blood pressure 
control: weight control; increased physical activity; alcohol moderation; sodium reduction; and emphasis on 
increased consumption of fresh fruits, vegetables, and low-fat dairy products. (Class I; Level of Evidence: B) 
b. Patients with blood pressure ≥140/90 mm Hg should be treated, as tolerated, with blood pressure 
medication, treating initially with beta-blockers and/or ACE inhibitors, with addition of other drugs as needed 
to achieve goal blood pressure. (Class I; Level of Evidence: A) 
 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Blood pressure should be measured in each individual several times, on several separate occasions. 
 Blood pressure target varies by assessment modality: resting blood pressure, home blood pressure, ambulatory 
monitoring blood pressure. 
 Blood pressure target for diabetes, renal failure patients may differ in comparison to CAD patients.  
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PROCESS INDICATOR NO: CR-14 
ASSESSMENT OF LIPID CONTROL 
Description Percentage of patients in CR who received individualized assessment of lipid control. 
Numerator The total number of enrolled CR patients for whom an assessment of lipid control was made.  
 
Enrollment is defined as patient attendance at a first CR program visit. 
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program.  
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Assessment of cardiovascular (CV) risk factors including dyslipidemia should be made at program entry and exit in 
order to evaluate and identify patients who are not at target according to Canadian guidelines. A period of at least 6 
weeks should pass before assessment of drug changes. Subsequently, medication changes should be done in the 
appropriate manner during the CR program in order to reach optimal CV risk factor goal. Communication should be 
made with the primary care provider as well as the pharmacist.  
 
Targets as defined by current Canadian secondary prevention guidelines (Treatment target is for LDL-C <2.0 mmol/L 
or > 50% reduction). 
 
Clinical Recommendation(s) 
CCS Dyslipidemia Guidelines 2012 
 All patients with evidence of atherosclerosis should undergo lipid profile screening. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Not all programs have MDs. 
 LDL target may be different depending of the CVD risk assessment (high vs. very high risk patient). 
 Alternative target to LDL: apoB vs. non-HDL. 
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PROCESS INDICATOR NO: CR-15 
ASSESSMENT OF ADIPOSITY 
Description Percentage of patients in CR program who received individualized assessment of adiposity. 
Numerator The total number of enrolled CR patients for whom an assessment of adiposity was made. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Both overweight and obesity are associated with a risk of death in cardiovascular (CV) disease. There is a positive 
linear association of body mass index with all-cause mortality. Assessment of CV risk factors, including excess body 
weight, should be made at program entry and exit in order to evaluate and identify patients who are not at target, 
according to WHO thresholds.  
 
One of the components of abdominal fat, namely visceral adipose tissue, is a metabolically active endocrine organ 
whose action impacts CV risk factors. Thus, assessment of waist circumference, measured in accordance with 
current Canadian Cardiovascular Society Lipid and Canadian Diabetes Association Guidelines, over and above body 
mass index, is warranted.  
 
Targets as defined by current Canadian guidelines (Goals: Body mass index: 18.5 to 24.9 kg/m
2
; Waist 
circumference: women<35 inches (<89 cm), men <40 inches (<102 cm)). 
 
Clinical Recommendation(s) 
European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (v2012) 
 Weight reduction in overweight and obese people is recommended as this is associated with favourable effects 
on blood pressure and dyslipidemia, which may lead to less CVD (class I, level A; Grade- Strong).  
 
AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic 
Vascular Disease: 2011 Update 
a. If waist circumference (measured horizontally at the iliac crest) is <35 inches (<89 cm) in women and <40 
inches (<102 cm) in men, therapeutic lifestyle interventions should be intensified and focused on weight 
management. (class I; Level of Evidence: B) 
b. The initial goal of weight loss therapy should be to reduce body weight by approximately 5% to 10% from 
baseline. With success, further weight loss can be attempted if indicated. (class I; Level of Evidence: C) 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 What index should be chosen for the assessment of adiposity (weight, body mass index, waist circumference, 
waist-to-hip ratio, waist-to-height ratio, bioimpedance)? 
 Method of assessment of waist circumference – ensure standardized measurement. 
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PROCESS INDICATOR NO: CR-16 
INDIVIDUAL ASSESSMENT OF BLOOD GLUCOSE CONTROL (HBA1C) 
Description Percentage of patients in CR who received individualized assessment of blood glucose control. 
Numerator The total number of enrolled CR patients for whom an assessment of glucose control was made. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patients without diabetes mellitus 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Assessment of cardiovascular (CV) risk factors, including fasting blood glucose and HbA1c, should be made at 
program entry and thereafter as recommended in order to identify and treat patients who are not at target. The CR 
setting represents an excellent opportunity for health care providers to monitor and manage diabetes mellitus (DM) 
because of the frequent contact and close relationship that personnel and patients usually develop. Improving 
glycemic control significantly reduces the risk of microvascular complications, and there is a relationship between 
increased levels of glycemia and cardiovascular events. 
 
Target indicative of control as defined by current Canadian Diabetes Association guidelines: hemoglobin A1c ≤7.0. 
Programs should aim to achieve HbA1c target levels in at least 90% of patients (benchmark). 
Clinical Recommendation(s) 
 AACVPR Statement “Recommendations for Managing Patients with Diabetes Mellitus in Cardiopulmonary 
Rehabilitation” 2012 
 A key recommendation for patients with diabetes mellitus is optimal blood glucose control. An important role of 
the CR team is to assess risk factors for recurrent coronary events and guide patients in risk modification. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Not all programs have MDs 
 Cost of measurement in non-diabetics 
 Criteria for screening for diabetes 
 Risk engine for the screening of diabetes? 
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OUTCOME INDICATOR NO: CR-17 
INCREASE IN EXERCISE CAPACITY 
Description 
The percentage of Cardiac Rehabilitation (CR) patients who achieved a half metabolic 
equivalent (MET) increase in their exercise capacity from the initial to the final exercise session. 
Numerator A subset of the denominator representing a number of patients who achieved a half 
metabolic equivalent (MET) increase in their exercise capacity from the initial to the final 
exercise session.  
Denominator The total number of patients who completed the CR Program in the reference period. 
 
To complete the CR program a patient must have attended at least some of the 
CR intervention components and have had a formal re-assessment  by the CR 
team at the conclusion of the CR intervention. See definition of CR intervention 
components in preamble. 
 
Exclusions 
• Patients who cannot walk on a treadmill unaided, or who cannot 
cycle on a bike ergometer. 
• Patients who do not meet the ACSM safety recommendations  for 
undertaking a stress test. 
Method of 
Calculation 
Numerator / Denominator * 100 
 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Systematic programs of CR that included prescribed exercise training can significantly improve patients’ 
functional capacity. Enhanced cardiovascular  fitness (evaluated by treadmill stress testing and expressed in 
METs) is associated with better survival and fewer CV events. The positive effect of exercise training and 
improved cardiometabolic  fitness, as a means of improving patient outcomes, is firmly grounded in the positive 
effects these interventions have on exercise vascular biology. A half MET improvement is related to health 
benefit. 
 
Reference: 
• Kavanagh, T., Mertens, D. J., Hamm, L. F., Beyene, J., Kennedy, J., Corey, P., & Shephard, R. J. (2002). 
Prediction of long-term prognosis in 12 169 men referred for cardiac rehabilitation.  Circulation, 106(6), 666-
671. 
• Myers, J., Prakash, M., Froelicher, V., Do, D., Partington, S., & Atwood, J. E. (2002). Exercise 
capacity and mortality among men referred for exercise testing. New England Journal of Medicine, 
346(11), 793-801. 
 Piepoli MF, Corra U, Benzer W, Bjarnason-Wehrens B, Dendale P, Gaita D, McGee H, Mendes 
M, Niebauer J, Zwisler AO, and Schmid J. 2010. Secondary prevention through cardiac 
rehabilitation: physical activity counselling and exercise training. Eur Heart J 31(16): 1967-1974. 
doi: 10.1093/eurheartj/ehq236 
 
Clinical Recommendation(s) 
Assessment of exercise capacity should be made at program entry and exit in order to evaluate 
change in exercise capacity. 
Reference : 
 Sanderson, B. K., Southard, D., & Oldridge, N. (2004). AACVPR consensus statement. Outcomes 
evaluation in cardiac rehabilitation/secondary prevention programs: improving patient care and 
program effectiveness. Journal of cardiopulmonary  rehabilitation, 24(2), 68. 
 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 Modality used to measure exercise capacity may vary by program which may inhibit cross-comparison  (i.e. 
6- minute walk test, graded exercise test, cardiopulmonary  test; measured capacity vs. estimated). 
 While exercise stress tests are recommended,  not all programs have MDs to supervise them. 
 Variation in exercise stress testing protocols from pre to post-program inhibits comparison over time. 
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 Symptom limits to tests inhibits ability to ascertain maximum capacity. 
 
 
 
 
 
 
OUTCOME INDICATOR NO: CR-18 
ADHERENCE TO CARDIAC REHABILITATION PROGRAM 
Description Percentage of prescribed CR exercise sessions completed by patient. 
Numerator The total number of scheduled centre-based exercise sessions attended during CR among 
enrolled patients. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
Denominator The total number of exercise sessions offered or prescribed to enrolled patients for a given 
scheduled centre-based CR program, to the point where a patient is discharged from the 
program. 
 
Program discharge is defined as patient participated in at least some of the program and the fi le 
was closed out by the CR team.  
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
All patients in CR should be encouraged to attend all sessions during CR, as the number of CR sessions attended 
correlates with improved prognosis (GOSPEL study; Hammill et al. Circ 2010;121:63; Martin et al. Circ 
2012;126:677). Given the complexity of CR program offerings, adherence to prescribed exercise can serve as a 
“proxy” measure for overall program adherence. Adherence to PA sessions during CR has been linked to increased 
longevity, reduced morbidity, and improved QoL.  
 
Clinical Recommendation(s) 
Canadian Association of Cardiac Rehabilitation guidelines, 3
rd
 Edition  
 Adherence and persistence with prescribed exercise, health behaviour interventions and pharmacological 
therapies (i.e., improvements in cardiometabolic fitness) is associated with significantly improved outcomes.  
Challenges to Implementation 
 Some programs prescriptions include non-supervised sessions which may be hard to confirm were completed 
and thus included in the database.   
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PROCESS INDICATOR NO: CR-26 
SMOKING CESSATION SUPPORT 
Description 
Percentage of CR patients who are current or recent smokers and who were referred for 
smoking cessation. 
Numerator The total number of patients discharged from CR who were current or recent (< 6 months) 
smokers at enrollment, and who were referred to a smoking cessation program. 
  
Enrollment is defined as patient attendance at a first CR program visit. 
 
An internal referral is defined as a referral to a member of the interdisciplinary CR team (e.g. 
psychologist, counselor, social worker). An external referral is defined as a referral to a mental 
health professional who is not part of the CR program. 
Denominator The total number of current or recent smokers at enrollment who were discharged from the CR 
program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
Period of 
Assessment 
At least annually.  
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
There is evidence illustrating that the identification and treatment of smokers can dramatically increase the chance of 
cessation, aiding in the secondary prevention of CAD. CAD patients often relapse within a year without assistance. It 
is recommended that patients be referred for cessation assistance. Health care providers should be knowledgeable 
with the principles and practice of smoking cessation; both smoking cessation pharmacology and behaviour 
modifications. Counselling and pharmacotherapy, alone or together, improve cessation success.  
 
Clinical Recommendation(s) 
“It is the view of CCS that all patients should have their smoking status systematically identified and documented and 
be offered specific assistance initiating a cessation attempt.”  
 
Reference: 
 Smoking Cessation and the Cardiovascular Specialist; Canadian Cardiovascular Society Position Paper. 
Pipe et al. Canadian J Cardiology. Volume 27, Issue 2, pg 132-137. March 2011 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 None 
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PROCESS INDICATOR NO: CR-30 
STRESS MANAGEMENT 
Description Percentage of CR patients who were referred to a stress management intervention. 
Numerator The total number of enrolled CR patients who were referred to a stress management 
intervention either within or outside the CR program. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
An internal referral is defined as a referral to an intervention delivered by qualified members of 
the CR team (e.g., psychologist, counselor, social worker). An external referral is defined as a 
referral to a programme, delivered by a qualified individual, or professional who is not part of the 
CR program. 
 
Denominator The total number of patients discharged from the CR program. 
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team. 
 
Exclusions: 
 Patients who have a documented patient-centered reason for not being offered stress 
management (i.e., perceive no difficulty with stress) 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Acute stress can cause ischemia. Reviews have demonstrated the benefits of stress management in CR in improving 
psychosocial outcomes of participants. Stress management interventions in a CR setting have been shown to 
improve psychosocial and CV risk outcomes in participants. In addition, they provide key life skills  which can be 
utilised to reduce future stress. Data on the efficacy of such interventions to reduce hard outcomes is contradictory 
(though generally null findings have been reported) and limited. Stress management is considered a key element of 
CR programs. 
 
Note, any intervention given must be empirically-validated and/or theoretically-based and should be given by 
someone qualified to deliver the intervention. 
Clinical Recommendation(s) 
Stress or psychosocial management is defined as a core component in both the AACVPR guidelines (Circulation. 
2000; 102: 1069-1073) and is a recommended element of the CACR guidelines (see Chapter 6). 
Method of Reporting 
The reported statistic will be a percentage 
Challenges to Implementation 
  None 
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STRUCTURE INDICATOR NO: CR-31 
MEDICAL DIRECTOR SUPERVISION 
Description Percentage of CR programs that have a physician medical director providing program oversight. 
Numerator The total number of CR programs with a physician Medical Director who is responsible for the 
oversight of the CR program.   
Denominator The total number of CR programs within Canada/province/regional health care authority. 
 
Period of 
Assessment 
At least annually. 
Sources of Data Audit of written program policies, review of program structure and delivery through interviews 
with medical director, clinical director, manager and / or clinical staff, or 
provincial/regional/national CR program survey 
Rationale 
The physician Medical Director is responsible to ensure that the policies and procedures are consistent with 
evidence-based standards and guidelines for the delivery of contemporary CR. 
 
The medical director works alongside clinical and administrative leadership to oversee delivery of CR services 
provided by a multidisciplinary and trans-disciplinary staff of health care professionals.  Physician to physician referral 
is often the pre-requisite medical pathway that connects patients in to the CR program from acute care or community-
based practice settings.  Taking action directly with the patient or referring source on findings from new medical 
assessments, changes in evidence based pharmacotherapies or laboratory/diagnostic testing will require physician 
input. Increasing age, complexity and co-morbidity of patients entering CR requires more direct physician 
engagement with screening and oversight of the program.  
 
Reference: 
 
 King et al. Medical Director Responsibilities for Outpatient Cardiac Rehabilitation / Secondary Prevention 
Programs: 2012 Update. A statement for healthcare professionals from the AACVPR and AHA. JCRP, 2012; 
32:410-419.  
Clinical Recommendation(s) 
The physician Medical Director is ultimately responsible for the medical well-being of the patients within the CR 
Program and provides oversight of safety, efficacy and connection with the referring medical community (reference: 
CACR Guidelines, 3
rd
 edition, p437, p410). 
 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 None 
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STRUCTURE INDICATOR NO: CR-32 
EMERGENCY RESPONSE STRATEGY 
Description 
The percentage of CR programs with a documented emergency response strategy and 
appropriately qualified staff. 
Numerator A subset of the denominator representing a number of CR programs that meet both of the 
following criteria: 
 
1.  An emergency response strategy enabling prompt defibrillation is in place to deal with 
medical emergencies. 
2. All clinical staff have current basic life-support (BLS) certification including use of 
Automated 
External Defibrillation (AED) devices. 
 
Denominator The total number of CR programs within Canada/province/regional health care authority. 
Method of 
Calculation 
Numerator / Denominator * 100 
 
Sources of Data Audit of written program policies, interviews with program staff, or provincial/regional/national 
CR program survey. 
Rationale 
Emergency response strategies are important since exercise training and or stress testing is associated with a 
small incremental risk over and above the co-incidental risk for a cardiovascular emergency experienced by any 
cardiac patient. Prompt defibrillation has been demonstrated to be the most effective form of management for 
cardiac arrest. Prompt defibrillation is often facilitated by other basic and advanced life saving support strategies 
to promote good outcomes in patients who have experienced cardiac arrest. 
 
Reference: 
 Thomas, R. J., King, M., Lui, K., Oldridge, N., Piña, I. L., Spertus, J., ... & Whitman, G. R. (2007). 
AACVPR/ACC/AHA 2007 Performance Measures on Cardiac Rehabilitation for Referral to and Delivery of 
Cardiac Rehabilitation/Secondary Prevention Services: Endorsed by the American College of Chest Physicians, 
American College of Sports Medicine, American Physical Therapy Association, Canadian Association of Cardiac 
Rehabilitation, European Association for Cardiovascular  Prevention and Rehabilitation, Inter-American  Heart 
Foundation, National Association of Clinical Nurse Specialists, Preventive .... Journal of the American college of 
Cardiology, 50(14), 1400-1433. 
 
Clinical Recommendation(s) 
CACR Guidelines, 3
rd
 Edition (Chapter 12: Program Administration and Human Resources, p.430) 
 All CR programs require a process in place that addresses site-specific facility equipment in conjunction with 
safety requirements and considerations 
 All CR programs require policies and procedures for the management of medical emergency situations. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 There may be variation in the response strategy, making comparison across CR programs difficult. 
For example, a policy and procedure for cardiac arrest; pre-arranged link to local ambulance service; 
and / or on-site automated external defibrillator (AED) devices. Moreover, for programs located in a 
hospital setting, there may be existing hospital-wide cardiac emergency response with more 
advanced resuscitation care protocols and equipment. 
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OUTCOME INDICATOR NO: CR-34 
COMMUNICATION WITH THE PRIMARY HEALTH CARE PRACTITIONER 
Description 
Percentage of CR patients with a documented communication between the CR program and 
primary health care practitioner (PHCP). 
Numerator The total number of discharged patients with at least one documented communication from the 
CR program to the primary health care practitioner.  
 
Program discharge is defined as patient participated in at least some of the program and the file 
was closed out by the CR team.   
Denominator The total number of patients discharged from the CR program. 
 
Exclusions: 
 Patients who died before being discharged from CR program. 
 Patients who are re-admitted to hospital before being discharged from CR program. 
 Patient has no primary health care provider. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
Communication between CR and PHCP may improve further management of patients’ cardiac risk by the PHCP.  A 
CR Program should have strategies in place to communicate CR participants’ status at entry/exit from the CR 
Program to their PHCP. Inter-current communication may be clinically warranted in some cases. It is recommended 
that the summative communication be received by the PHCP prior to the patient’s subsequent visit. Communication 
should be sent to the PHCP at program exit regardless of patient continuation in a maintenance program.  
Clinical Recommendation(s) 
BACPR Core Components and Standards, 2012 
 On programme completion there should be a formal assessment. This should be communicated by discharge 
letter to the referrer and the patient as well as those directly involved in the continuation of healthcare provision. 
 There should be communication and collaboration between primary and secondary care services to achieve the 
long-term management plan. 
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
 None 
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OUTCOME INDICATOR NO: CR-37 
CARDIAC REHABILITATION PROGRAM COMPLETION 
Description Percentage of patients enrolled in CR who completed the program. 
Numerator The total number of enrolled patients who completed the CR program. 
 
To complete the CR program a patient must have attended at least some of the CR intervention 
components and have had a formal re-assessment by the CR team at the conclusion of the CR 
intervention.  
 
The CR intervention components are defined as per the BACPR Core Components, namely: 
health behaviour change and education, lifestyle risk factor management, psychosocial health, 
medical risk factor management, and cardio-protective therapies. 
Denominator The total number of patients enrolled in the CR program. 
 
Enrollment is defined as patient attendance at a first CR program visit. 
 
Exclusions: 
 Patients that experience a recurrent cardiac or other clinical event that prevents a patient 
from completing the CR program such as a comorbid life-threatening condition, a serious 
mental illness, or the inability to ambulate. 
Period of 
Assessment 
At least annually. 
Sources of Data Program databases and/or Canadian Cardiac Rehabilitation Registry. 
Rationale 
A dose-response relationship between CR program attendance and reduced morbidity and mortality has been 
established.  
 
Ideally, at program completion participants will have attained their CR goals, be meeting exercise and nutrition 
guidelines, and be within recommended targets for blood pressure, and lipids. 
Clinical Recommendation(s) 
CACR guidelines, 3
rd
 Edition  
 Adherence and persistence with prescribed exercise, health behaviour interventions and pharmacological 
therapies (i.e., improvements in cardiometabolic fitness) is associated with significantly improved outcomes.  
Method of Reporting 
The reported statistic will be a percentage. 
Challenges to Implementation 
  Program variation in terms of CR intervention, and comprehensiveness of post-program assessment. 
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Appendix F: Discharge Survey sections utilized 
 
SECTION A: USUAL ACTIVITIES 
Instructions:   The following questions have to do with your current activity status.  
Please circle     Yes     or      No     in response to each question.  
 
1. Can you take care of yourself, that is, eating, dressing, bathing or using the 
toilet? 
Yes No 
2. Can you walk indoors, such as around your house? Yes No 
3. Can you walk a block or two on level ground? Yes No 
4. Can you climb a flight of stairs or walk up a hill? Yes No 
5. Can you run a short distance? Yes No 
6. Can you do light work around the house like dusting or washing dishes? Yes No 
7. Can you do moderate work around the house like vacuuming, sweeping floors, or 
carrying in the groceries? 
 
Yes No 
8. Can you do heavy work around the house like scrubbing floors, or lifting or 
moving heavy furniture? 
 
Yes No 
9. Can you do yard work like raking leaves, weeding or pushing a power mower? 
 
Yes No 
10. Can you have sexual relations? Yes No 
11. Can you participate in moderate recreational activities like golf, bowling, 
dancing, doubles tennis, or throwing a baseball or football? 
 
Yes No 
12. Can you participate in strenuous sports like swimming, singles tennis, football, 
basketball or skiing? 
 
Yes No 
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SECTION M: CARDIOVASCULAR REHABILITATION PARTICIPATION 
 
Instructions: Cardiovascular rehabilitation (CR) is an outpatient program of structured exercise and 
education to maximize your recovery. Please check the appropriate box in response to each question. If 
your checked answer has an arrow leading to another box, answer the questions in the attached box.  
Please print any written answers clearly. 
 1.   Did you attend a cardiovascular rehabilitation assessment (intake appointment)?  
 
 Yes 
  
 No 
 
 
 
2. Did you participate in cardiac rehabilitation?  
 
 Yes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(If Yes) 1.Where? _____________________________________ 
2. How many minutes did you take you to travel there one-way? _______ 
mins 
 
 
 
 
 
 
(If No) Why not? 
 
 
 
 
 
 
(If Yes) 1. What type of program did you attend? (please  one answer) 
 Women-only hospital-based 
 Men and women hospital-based 
 Home-based 
 
2. Approximately how many weeks passed between being discharged from 
hospital, and starting the cardiac rehab program? ___________ wks 
 
3. Did you consider this to be an acceptable or unacceptable length of time 
to wait for cardiac rehab? 
 
 acceptable 
 unacceptable 
 
4. Approximately what percentage of cardiac rehabilitation sessions 
did you complete on the phone or at the hospital?  
                             % of sessions completed  
 
 
 
Why?  
